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Abstract in German
 
 
Bislang ist nicht bekannt, in welchem Differenzierungsstadium reife T- Zell- Leukämien/ 
Lymphome initiert werden. Frühere Studien in unserer Gruppe haben eine Resistenz reifer T- 
Zellen gegenüber der Transformation gezeigt. Nun sollte das transformierende Potential von 
NPM-ALK, p21SNFT und des viralen Onkoproteins Tax in reifen T- Zellen weiter untersucht 
werden. Zunächst wurden die Effekte der drei Proteine auf das Zellwachstum in vitro 
untersucht, indem humane T- Zelllinien mit gammaretroviralen Vektoren, die diese Gene 
kodierten, transduziert wurden. Für alle drei Gene konnte kein proliferationsfördernder Effekt 
beobachtet werden. Im zweiten Teil des Projekts wurden murine reife T- Zellen oder 
hämatopoetische Stammzellen ( HPCs/ HSCs) mit diesen Vektoren transduziert und in Rag-1 
knockout Mäuse transplantiert. Alle Mäuse, die mit NPM-ALK transduzierten monoklonalen 
reifen T- Zellen (OT-1) transplantiert wurden, entwickelten Leukämien/ Lymphome. Im 
Gegensatz dazu entwickelten nur wenige der mit NPM-ALK transduzierten polyklonalen T- 
Zellen oder HPCs/ HSCs transplantierten Tiere Leukämien/ Lymphome. In der p21SNFT 
Gruppe zeigten nur zwei der Mäuse, die mit transduzierten OT-1 T- Zellen transplantiert 
wurden, Leukämien/ Lymphome. Diese exprimierten eGFP in hohem Maße und 
interessanterweise auch CD19. Für alle Tax transplantierten Tiere konnten bislang keine 
Leukämien/ Lymphome beobachtet werden. Das weiteren zeigten diese Tiere keine eGFP 
Expression im peripheren Blut. 
Zusammenfassend zeigen diese Resultate, dass monoklonale T- Zellen verglichen mit 
polyklonalen T- Zellen nach gammaretroviralem Transfer von NPM-ALK  oder  p21SNFT 
leichter transformierbar sind.          Abstract  6
Abstract in English
 
 
To date it is not clear at which stage of differentiation mature T cell leukaemia/lymphoma is 
initiated. Previous studies in our group showed that mature T cells are relatively resistant to 
transformation. We wanted to further investigate the transformation potential of NPM-ALK, 
p21SNFT and the viral oncoprotein Tax on mature T cells. First, we analyzed the effects on T 
cell growth in vitro after transducing human T cell lines with gammaretroviral vectors 
encoding these genes. No growth or proliferation promoting effect of all three genes was 
observed. In the second part of the project, we transduced murine, mature T cells and/or 
haematopoietic stem cells (HPCs/HSCs) and transplanted these cells into Rag-1 deficient 
recipients. All mice transplanted with NPM-ALK transduced monoclonal mature T cells (OT-1) 
developed leukaemia/lymphoma. In contrast, only few NPM-ALK transduced polyclonal T cell 
and HPC/HSC transplanted mice developed leukaemia/lymphoma. From the p21SNFT 
group, only two mice transplanted with transduced OT-1  T cells developed 
leukaemia/lymphoma, which showed high eGFP and interestingly CD19 expression. No 
malignancies were observed in Tax transplanted animals so far. Furthermore, the recipients 
do not show any eGFP marking in the periphery.  
In conclusion, our results show that compared to polyclonal T cells, monoclonal T cells are 
transformable after gammaretroviral transfer of NPM-ALK and p21SNFT.  Introduction  7
1.  Introduction
 
1.1   Haematopoiesis 
1.1.1 Definition of haematopoiesis 
Haematopoiesis is a Greek word that means production of blood (haimatos - blood, poiesis - 
production). All blood components are derived from the haematopoietic stem cell. Growth 
factors and cytokines play an important role in the maturation of different cells of blood and 
the immune system. During the embryonic period of life, the haematopoiesis begins in the 
extraembryonic mesoderm. During mid gestation, the main haematopoetic organs are liver 
and spleen. At the end of the gestation, it takes place in the bone marrow, where it remains 
throughout the adult life [1,2]. 
Blood contains different types of cells to fulfil different functions. The haematopoietic stem 
cell (HSC) has the ability of self-renewal and differentiation to all blood cell types [1,3,4]. In 
figure 1, the hierarchy of haematopoiesis is shown. The HSC can maintain haematopoiesis of 
an organism due to its pluripotent and lifelong self-renewal ability. It is accepted that the 
number of these HSCs is relatively conserved within the group of the mammals [5]. This was 
described for cat, mouse and humans and is about 10.000-20.000 HSCs per organism. The 
monoclonal regeneration from each HSC of the complete haematological system takes about 
15 cell divisions. This points at the enormous stress, regeneration ability and transformation 
resistance of HSCs. From this cell two main lines are derived, the lymphoid (common 
lymphoid progenitor, CLP), which inturn differentiates to give rise to T cells, B cells, and 
natural killer cells, and the myeloid (common myeloid progenitor, CMP), which differentiates 
into neutrophils, eosinophils, monocytes/macrophages, basophils, erythrocytes and platelets. 
For myeloid leukaemias there is growing evidence that they originate in haematopoietic stem 
cells/haematopoietic  progenitor cells (HSCs/HPCs) or early myeloid progenitors [6,7]. 
However, compared with other mature cell lineages, fully differentiated lymphocytes claim a 
special position in haematopoiesis. They show long life-spans, sustained proliferation and the 
ability of self-renewal [8]. For B cells it was recently shown that fully mature B lymphocytes 
can still be transformed [9]. However, for mature T cells, several observations indicate that 
these cells are less susceptible to transformation than HSCs/HPCs. Here, we describe the 
development and maturation of T cells in more detail (see 1.1.2) as they are used in the 
available work to further investigate the transformation susceptibility of mature T cells.   Introduction  8 
 
 
Figure 1. Hierarchy of haematopoiesis. The pluripotent haematopoietic stem cell has the 
capability of self-renewal, and it gives rise to all blood-cell types. The T lymphoid lineage in 
mature stage is highlighted (blue box), since experiments in the available thesis are mainly 
focused on these cells. Modified according to [10].  
 
1.1.2 Development of mature T cells  
T lymphocytes play an important role in the adaptive immune response. These CD3+ cells 
express a T cell receptor (TCR) on their cell surface which recognizes foreign antigens. T 
lymphocytes do not recognize free but cell bound antigens, which are presented to them by 
other  cells  (APC,  antigen  presenting  cells)  by  means  of  MHC  (major  histocompatibility 
complex) molecules [11]. While these cells develop in the thymus, they rearrange the genes 
for the TCR. Either TCRα and TCRβ or TCRγ and TCRδ can be rearranged by the activity of 
the  recombinase  enzymes  RAG-1  and  RAG-2  [11,12].  The  factors  involved  in  the 
rearrangement  of  TCRα  and  TCRβ  or  TCRγ  and  TCRδ  are  not  well-understood.  This 
rearrangement leads to a very large diversity within the T cell population. Theoretically, a 
diversity of approximately 10
18 different TCRs is possible, whereby for each antigen a specific 
T cell clone with a suitable TCR is conceivable. But the large diversity harbours the risk of 
self-reactivity. Therefore, during the selection process in T cell development, the essential 
self-tolerance and the broad spectrum against potential pathogens are maintained. During its 
development, the undifferentiated T cell progenitor migrates from the bone-marrow to the Introduction  9
thymus and goes through two fundamental selection stages: the positive and negative 
selection. The thymus stroma carries essential molecules like interleukins or MHC proteins 
for the T cell-development that act by direct cell cell contact. The developing lymphocytes 
whose receptors interact weakly with self antigens in connection with self MHC molecules, or 
bind in a particular way, receive a signal that enables them to survive; this type of selection is 
known as positive selection. This selection ensures that an individual will have a repertoire of 
T cells that can respond to peptides bound to his or her own MHC molecules. 
In contrast, lymphocytes whose receptors bind strongly to self antigen-MHC complex receive 
signals that lead to their death via apoptosis; this type of selection is known as negative 
selection. Strongly self-reactive lymphocytes are therefore removed from the repertoire 
before they become fully mature and might initiate damaging autoimmune reactions. In this 
way immunological  self-tolerance  is established to ubiquitous self antigens [13]. In the 
thymus, the earliest cell population does not express CD4, CD8 and T cell receptor complex 
molecules (CD3, and the TCR 
 
and 
 
chains), they are called  double-negative  (DN) 
thymocytes. These precursor cells give rise to two T cell lineages: the minority population of 
:
 
 
T cells (which lack CD4 or CD8 even when mature), and the majority  :
 
T cell lineage. 
The development of prospective  :
 
T cells proceeds through stages in which both CD4 and 
CD8 are expressed by the same cell; these are known as  double-positive  (DP) thymocytes. 
At first, double-positive cells express the pre-T cell receptor (p  :
 
T). These cells enlarge 
and divide. Later, they become small resting double-positive cells in which low level of T cell 
receptor ( : ) itself is expressed. Most of the thymocytes (about 98%) die within the thymus 
after becoming small double-positive cells. Those cells whose receptors can interact with 
self-peptide:self-MHC class I molecular complexes lose the expression of CD4 and become 
CD8 single positive, while the cells whose receptors can interact with self-peptide:self-MHC 
class II  molecular complexes lose the expression of CD8 and become CD4 single positive. 
The outcome of this process is the  single positive  (SP) thymocytes, which after maturation 
are exported from the thymus as mature single positive CD4 or CD8 T cells [14-16].  
1.2   Malignant diseases of the blood 
Malignant proliferative diseases constitute the most important disorders of the blood. They 
are organized in two common broad categories, which are described as below:  Introduction  10
1.2.1 Myeloid neoplasms 
These neoplasms arise from haematopoietic progenitor cells that give rise to cells of the 
myeloid (i.e., erythroid, granulocytic, and/or thrombocytic) lineage. There are further three 
categories of myeloid neoplasia: acute myelogenous leukaemia, in which immature 
progenitor cells accumulate in the bone marrow; myelodysplastic syndromes, which are 
associated with ineffective haematopoiesis and resultant peripheral blood cytopenias; and 
chronic myeloproliferative disorders, in which increased production of one or more terminally 
differentiated myeloid elements (e.g., granulocytes) usually leads to elevated peripheral 
blood counts [17].  
1.2.2 Lymphoid neoplasms 
These are the neoplasms of lymphoid cells, the T cells,  B cells and NK cells. The vast 
majority of these neoplasms (80-85%) is of B cell origin, most of the remainder being T cell 
tumors; only rarely are tumors of NK origin. 
Lymphoid neoplasms encompass a diverse group of entities. In 1994, a group of 
haematopathologists, oncologists, and molecular biologists came together to create the 
Revised European-American Classification of Lymphoid Neoplasms (REAL). Of importance, 
this classification scheme incorporated objective criteria, such as immunophenotype and 
genetic aberrations, together with morphologic and clinical features, to define distinct 
clinicopathologic entities. Most entities in the REAL classification can be diagnosed 
reproducibly by experienced pathologists and categorize patients into good or bad prognostic 
groups. More recently, an international group of haematopathologists and oncologists 
convened by the World Health Organisation (WHO) reviewed and updated the REAL 
classification, resulting in the inclusion of a number of additional rare entities [17]. The WHO 
classification sorts the lymphoid neoplasms into four broad categories, based on their cell of 
origin and immunophenotype:  
1.  Precursor B cell neoplasms (neoplasms of immature B cells) 
2.  Peripheral B cell neoplasms (neoplasms of mature B cells) 
3.  Precursor T cell neoplasms (neoplasms of immature T cells) 
4.  Peripheral T cell and NK cell neoplasms (neoplasms of mature T cells and natural 
killer cells). The sub types of this neoplasm are as under:  
 
Adult T cell leukaemia/lymphoma 
 
Anaplastic large cell lymphoma 
 
Mycosis fungoides/Sezary syndrome Introduction  11
 
Large granular lymphocytic leukaemia 
 
T cell prolymphocytic leukaemia 
 
Peripheral T cell lymphoma, unspecified 
 
Angioimmunoblastic T cell lymphoma 
 
Enteropathy-associated T cell lymphoma 
 
Panniculitis-like T cell lymphoma 
 
Hepatosplenic   T cell lymphoma 
 
NK/T cell lymphoma, nasal type 
 
NK cell leukaemia  
The immature B cell and T cell leukaemia/lymphoma originate in the lymphoid progenitor 
cells in the bone marrow and the thymus respectively. For the mature B cell neoplasms, it 
has recently been shown that mature B cells are transformable [9]. But for the mature T cell 
neoplasms, it has not yet been known whether they originate from the mature T cells or the 
progenitor cells. To investigate this question, we have used the following potent T cell 
oncogenes in the available work:  
1.3   Used potent T cell oncogenes 
 
NPM-ALK, the fusion oncogene 
 
Tax, the HTLV-1 viral oncoprotein 
 
p21SNFT (T cell potential oncogene)  
1.3.1 NPM-ALK and anaplastic large cell lymphoma 
NPM ALK (nucleophosmin-anaplastic lymphoma kinase) is a fusion oncogene derived from 
the chromosomal translocation t(2;5)(p23;q35). This translocation fuses the gene encoding 
ALK receptor tyrosine kinase located on chromosome 2p23 with the housekeeping gene 
nucleophosmin (NPM) on chromosome 5q35. NPM-ALK chimeric gene encodes a 
constitutively activated tyrosine kinase that is oncogenic [18]. The ALK is the oncogene of 
most anaplastic large cell lymphomas (ALCL), deriving transformation through many 
molecular mechanisms. Nevertheless, ~15-40% of ALCL do not express ALK or other 
recurrent translocations. Approximately 70-80% of ALK-positive ALCLs express the NPM
ALK fusion protein, while the remaining 20-30% of ALK-positive ALCLs express other fusions 
like TPM3-ALK, TFG-ALK and CTLC1-ALK. ALCL has a peak incidence in childhood, Introduction  12
accounting for approximately 40% of NHL cases diagnosed in paediatric patients, whereas it 
accounts for <5% of NHL in adults and it is seen mostly in males.    
Figure 2. NPM-ALK and Ras ERK Pathway. Mitogenic signalling by NPM ALK is mainly due to the 
activation of the Ras extracellular signal regulated kinase (ERK) pathway through the direct binding of 
insulin receptor substrate 1 (IRS1), SRC homology 2 domain-containing (SHC) and SRC to specific 
tyrosine residues of ALK. The SHP2 GRB2 (growth factor receptor-bound protein 2) complex interacts 
with ALK and SHC to enhance phosphorylation of ERK1 and ERK2 through SRC. Phospholipase C- 
(PLC ) is directly bound and activated by ALK to trigger mitogenic stimuli by the generation of 
diacylglycerol (DAG) and inositol triphosphate (IP3), which, in turn, mobilize calcium stores from the 
endoplasmic reticulum and activate protein kinase C (PKC). ALK-induced mammalian target of 
rapamycin (mTOR) activation is transduced through the ERK signalling pathway and ends in the 
phosphorylation of the mTOR targets ribosomal protein S6 kinase (p70S6K) and S6 ribosomal protein 
(S6RP), which in turn stimulate protein translation and ribosome biogenesis. Activation of mTOR also 
leads to phosphorylation and inactivation of the eukaryotic initiation factor 4E-binding protein 1 
(EIF4EBP1), dissociating EIF4EBP1 from the RNA cap-binding protein EIF4E, thus promoting cap-
dependent translation of mRNA. Note that the NPM ALK fusion protein is not drawn to scale. Potential 
therapeutic targets (indicated by red inhibitory arrows) are already being validated in clinical trials. 
JNK: JUN N-terminal kinase; SOS: son of sevenless. Modified according to [19].  
NPM-ALK exerts its oncogenic effects via three main well characterized pathways [19]: 
1.  Ras extracellular signal regulated kinase (ERK) pathway which leads to mitogenic      
signaling. 
2. Phosphatidylinositol 3-kinase (PI3K) pathway which results in the antiapoptotic 
signals.  
3. Janus kinase 3 (JAK3) STAT3  pathway  which  leads  to  increased  survival  and                
proliferation. 
Overall, the Ras ERK pathway is essential mostly for ALCL proliferation which is described 
in more detail in the figure 2, whereas the JAK3 STAT3 pathway and the PI3K Akt pathway 
have been shown to be vital primarily for cell survival and phenotypic changes.  Introduction  13
1.3.2 Tax and adult T cell leukaemia/lymphoma  
Tax is a viral oncoprotein that is encoded by the Human T cell leukaemia virus type 1 (HTLV-
1). The Tax oncoprotein causes mature T cell malignancy, the adult T cell 
leukaemia/lymphoma (ATL). Only a small minority of HTLV-1-infected dividuals progress to 
ATL. Indeed, the cumulative risks of developing ATL among virus carriers are estimated to be 
approximately 6.6% for males and 2.1% for females. Tax exerts its oncogenic effects via 
different pathways to cause the increased cell proliferation, abnormal cell cycle, DNA 
damage and inhibition of apoptosis (see figure 3) [20,21].     
Figure 3. Pleiotropic activities of Tax. The oncogenic effects of Tax via different pathways are 
depicted which lead to increased cell proliferation, abnormal cell cycle, DNA damage and inhibition of 
apoptosis.  
The HTLV-1  Tax protein is required for the virus to transform cells [22]; however, Tax 
transcripts are detected in only ~40% of all ATLs. Analyses of HTLV-1 proviruses and Tax 
transcripts in ATL cells revealed three ways in which cells can silence Tax expression, which 
are: 
(i) Accumulation of nonsense mutations, insertions and deletions in Tax  [23,24].  
(ii) Silencing viral transcription by DNA methylation of the Provirus [24,25]. 
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(iii) Deletion of the proviral 5 LTR  [26].  
The currently accepted view for the silencing of Tax expression by the cells is that Tax is 
needed early after infection with HTLV-1 to initiate transformation, but is not required later to 
maintain the transformed phenotype of ATL cells. As Tax is the main target of the host s 
CTLs (cytotoxic T lymphocytes), cells that down-regulate Tax expression (using one of the 
three genetic or epigenetic means described above) have an advantage in evading 
immunosurveillance and are preferentially selected in vivo during disease progression [24].  
1.3.3 p21SNFT (T cell potential oncogene) 
p21SNFT (21-kDa small nuclear factor isolated from T cells) is a human protein of the basic 
leucine zipper family. The over expression of p21SNFT causes specific repression of both 
human IL-2 promoter activity and the production of IL-2 by activated Jurkat cells. IL-2 
(interleukin 2) is the major autocrine and paracrine growth factor for T cells and its production 
is indicative of T cell activation. IL-2 is highly regulated by multiple transcription factors, 
particularly AP-1, which coordinately activate the IL-2 promotor. The transcription factor AP-1 
consists of two heterodimers, the Fos and the Jun. p21SNFT competes with the Fos protein 
for Jun dimerization. This structural change in the AP-1 by p21SNFT causes repressive effect 
on the IL-2 promotor and thereby IL-2 production [27]. But surprisingly, microarray analysis 
has shown that p21SNFT is up-regulated in T cell leukaemia/lymphoma [28]. To investigate 
its potential leukemogenic effects, we have transduced this gene into murine stem cells and 
mature T cells.   
1.4   Gene Transfer  
1.4.1 Definition of gene transfer 
In broad term, gene transfer is the transfer of one DNA molecule to another DNA molecule. It 
is used for two main purposes, gene therapy and research. Here, we focus on gene transfer 
into cells, for which there are different methods which are described as below (see section 
1.4.2).  
1.4.2 Methods for gene transfer 
Viral and non viral methods can be used for gene transfer (see figure 4). In viral methods, 
selected viral genomes are used to carry the gene of interest. Different viruses are used for 
this purpose (see section 1.4.3). The non viral methods consist of nacked DNA, DNA/Lipid: Introduction  15
Liposomal complex and bacterial vector methods. The genetic information is transferred by 
two different procedures, ex vivo or in vivo. In ex vivo gene transfer, the target cells are 
genetically modified (with gene of interest) out side the body and then transplanted back to 
the patient. In contrast to this, in in  vivo gene transfer, the genetic information (gene of 
interest) is directly applied to the patient via different methods like local injection, systemic 
infusion, or gene gun.    
Figure 4. Gene Transfer-Vectors/-Methods.  Non viral methods: Nacked DNA (1), DNA/Lipid: 
Liposomal complex (2), Bacterial vector (5). Viral methods: Adenoviral vector (3), Retroviral vector (4).  
Here, we describe the viral methods as they are used in the available work (see 1.4.3).  
1.4.3 Viral Gene-Transfer Vectors 
Viral gene transfer vectors are derived from multiple viruses: adenoviral vectors, retroviral 
vectors derived from mouse retroviruses or lentiviruses, parvoviral vectors based on adeno-
associated viruses, vectors derived from vaccinia virus, baculovirus, simian virus 40, epstein 
barr virus or herpes simplex virus.  
Retroviral and adenoviral vectors are most widely used. However, only the retroviral vectors 
ensure  a stable and persistent genome integration [29]. Retroviral vectors have some 
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disadvantages, like, their small transgene capacity of approximately 8-10kb. Further, they 
show a high recombination and mutation rate. They, with the exception of lentiviral vectors, 
can infect only dividing cells. During vector production, replication competent retrovirus can 
be generated [30]; but, the use of  three plasmid system enables  production  of  replication-
incompetent viruses. In table 1,  some important characteristics of viral vectors are listed 
[31,32].  
Table 1.  Major groups of retroviral vectors.                   
* Adeno-associated Viruses. # except Lentiviral vectors (18 kb).  
In this thesis, gammaretroviral vectors were used, derived from murine leukaemia viruses 
from the genus of the gammaretrovirus.  
1.5   Retroviruses and their use in gene-transfer  
1.5.1 Retroviruses and their genome  
Retroviruses belong to the family of enveloped RNA viruses. They `reverse transcribe' (RT) 
their genome from RNA to DNA [33]. The virion measures 120 nm in diameter and contains 
two identical copies of positive strand RNA genome complexed with Nucleocapsid proteins. 
The Nucleocapsid, which is the inner portion of the virion, also contains Reverse 
Category  Retrovirus AAV*  Adenovirus Vaccinia-
Virus 
Herpes 
virus 
Autonomous 
Parvovirus 
Genome  ssRNA  ssDNA dsDNA  dsDNA  dsDNA ssDNA 
Transgene     
capacity 
8-10kb  <5kb 8-30kb  25kb  40-
150kb 
<4kb 
Titer  10
8  10
10  10
11  10
8  10
7  10
8 
Genome    
integration 
yes  no, 
>10% 
no  no  no  no 
Transduction 
(quiescent   
cells) 
no
 #  yes  yes  yes  yes  no 
Immune 
reaction 
light  strong  strong  strong  strong  unknown Introduction  17
transcriptase (RT), Integrase (IN) and Protease (PR) proteins. A protein shell, formed by 
Capsid proteins, encloses the Nucleocapsid and delimits the viral core [34]. Matrix (MA) 
proteins form a layer outside the core and interact with an envelope consisting of a lipid 
bilayer, which surrounds the viral core particle. The envelope originates from the cellular 
membrane and incorporates viral Envelope glycoproteins (Env). The Envelope glycoprotein, 
responsible for the virus interaction with the specific receptor, is the only viral protein on the 
surface of the particle. It is formed by two subunits: TM (transmembrane), which anchors the 
protein into the envelope membrane, and SU (surface), which binds to the cellular receptor. 
Figure 5 shows the structure of a retroviral particle.   
Figure 5: Structure of a retroviral particle. Gag proteins: Matrix-Protein (MA), Capsid (CA), 
Nucleocapsid (NC); Pro-Pol proteins: Protease Protein (PR), Integrase (IN), Reverse Transcriptase 
(RT); Env Protein: Transmembrane-Protein (TM), Surface-Proteine (SU).  
In the genome of all retroviruses, the basic translated region is organised in four genes: 
1.  Gag, which encodes three main structural proteins: Matrix (MA), Capsid (CA) and 
Nucleocapsid (NC).  
2.  Pro, which encodes the Protease (PR), responsible for gag and gag-pol cleavage and 
the maturation of the viral particles during or after their budding.  
3.  Pol, which encodes the enzyme Reverse transcriptase (RT), responsible for reverse 
transcription of the viral RNA to DNA during the infection process, and Integrase (IN), 
which catalyses the integration of the proviral DNA into the host genome.  
4.  Env, which encodes two subunits of the Envelope  glycoprotein:  surface (SU) and 
transmembrane (TM).  
In addition to gag, pro, pol, and  env,  complex retroviruses,  such  as  lentiviruses  have 
accessory genes, whose concerted activities regulate viral gene expression, assembly of Introduction  18
infectious particles and modulate viral replication in infected cells. Together with the genes 
encoding the viral proteins, the retroviral genome is flanked by cis-acting sequences such as 
two LTRs (long terminal repeats), which contain elements required to drive gene expression, 
reverse transcription and integration into the host chromosome (Figure 6).    
     
 
 
Figure 6. RNA genome and the integrated provirus of a gammaretrovirus. RNA viral genome is 
reverse transcribed into a DNA provirus by the activity of the viral Reverse transcriptase. During the 
RT process, U3 and U5 regions are duplicated and give rise to two identical LTRs (long terminal 
repeats). The dashed line between pro and pol indicates that the two genes share the open reading 
frame. Cap: 5
 
capping. SD: splice donor site. SA: splice acceptor site. PPT: polypurine tract. PBS: 
primer binding site. A(n): poly(A) tail.  : packaging signal.  
The R region forms a direct repeat at both ends of the  RNA  genome and provides the 
homology sequence necessary for strand transfer during reverse transcription process. R at 
the 3
 
of the genome is polyadenylated with 50-200 noncoding adenylate residues. During 
the reverse transcription process, the U5 and U3 regions are duplicated. The U3 region 
contains promoter and enhancer elements that regulate gene expression. The untranslated 
region (leader region) at the 5  end of the genome contains a primer binding site (PBS), 
located next to the 3  end of the U5, complementary to the 3
 
terminus of the primer t-RNA 
which is used by the RT to initiate reverse transcription. A packaging signal 
 
sequence, 
required for the specific packaging of the RNA into newly formed virions, is located partly in 
leader region and partly in the first portion of the translated gag region. A polypurine tract 
(PPT), located upstream of U3, functions as the site of the initiation of the positive strand 
DNA synthesis, during reverse transcription [35].  
1.5.2 Life cycle of retroviruses 
The life cycle of a retrovirus begins with its interaction with the host cell surface (Figure 7). 
The binding of the viral glycoprotein to a specific receptor complex on the cell surface causes Introduction  19
virus and cell membranes to fuse and the viral particle to be internalised. After virus-cell 
membrane fusion, the virus core is released into the cytoplasm. The viral core is partially 
degraded to form a large nucleoprotein particle containing the viral genome (preintegration 
complex) and is transported into the nucleus.    
Figure 7. Retrovirus life cycle.    The life cycle is completed with seven stages, which are: (1) 
Receptor binding, (2) Membrane fusion, (3) Reverse transcription, (4) Integration in the host genome, 
(5) Viral assembly, (6) Budding of viral particles, (7) Maturation of viral particles. Modified after [36]  
The process of entry into the nucleus differs between oncoviruses (e.g. MLV) and lentiviruses 
(e.g. HIV). For HIV-1, it was established that efficient transport to the nucleus is active [37] 
and uses the cellular nuclear import machinery. MLV entry to the nucleus was reported to be 
mitosis-dependent [38, 39]. It was therefore assumed that MLV, and perhaps all oncoviruses, 
cannot transit through the pores of the nuclear membrane but gain the access to the nuclear 
area only during mitosis, when the nuclear membrane is disassembled. During this process, 
the viral RNA is reverse transcribed into a double stranded proviral DNA. The provirus is 
permanently integrated as part of the host genome, which is then transcribed to give rise to 
new viral genomic RNA and hence to all viral proteins required for the formation of new 
virions.  Subsequently, viral RNA transcripts undergo splicing events in the cell nucleus, 
similarly to the host transcripts. Simple retroviruses can undergo single splicing, as in the 
case of MLV, which generates spliced mRNA expressing env. More complicated splicing 
occurs in complex retroviruses for the generation of the accessory proteins. The packaging 
signal ( ) in the viral RNA allows encapsidation of the unspliced RNA only, [40-42].   After 
assembly of the proteins around the viral RNA, the viral particle undergoes budding process 
from the cell membrane and takes the Env-protein. Within this particle, Protease catalyses Introduction  20
the polyproteins into the individual proteins like, MA, IN, RT, NC and CA. The virus particle is 
mature now to infect further cells with its Env receptor. 
1.5.3 Production of replication incompetent retroviral particles 
The  three-plasmid system  allows the production of replication-incompetent viruses by a so-
called packaging cell line (Figure 8) [43].   
                            
Figure  8. Three-plasmid packaging system for the production of replication-incompetent     
retroviral vectors. Viral particles are produced by transfection of two helper plasmids, which do not 
contain a packaging signal, and a transgene encoding plasmid that contains a packaging signal but 
does not code for any viral proteins. Transfected packaging cells produce the required gag/pol and env 
proteins for viral particle production. The transgenic vector is replicated and packaged into the virions. 
Thus, viral particles are produced that only contain the transgenic vector but no genetic information for 
viral replication or pathogenicity factors.  
This cell line is transfected with a vector that only contains the transgene and the packaging 
signal ( ) but does not code for any viral proteins. In parallel, two further plasmids are 
transfected into the packaging cell line coding for env and gag/pol, respectively. These two 
plasmids contain the information for the production of gag/pol and env proteins for viral 
particle production but do not possess the packaging signal. Therefore, the transgenic vector 
is replicated and packaged into the virions. Thus, viral particles are produced that only 
contain the transgenic vector but no genetic information for viral replication or pathogenicity 
factors. The produced viral particles are used for transduction of target cells.  
For the selective transduction of a certain cell type, replication-incompetent viruses can be 
targeted by pseudotyping. This process describes the production of viral vectors with a 
foreign envelope gene (VSV-G, gp160, HA). Pseudotyped viral particles can only infect cells 
expressing the respective receptor for the viral envelope protein.          
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Objective     
The objective of my thesis was to investigate the stage of maturation at which the mature T 
cell leukaemia/lymphoma is initiated, because it is not yet clear whether these malignancies 
originate from the HSC/HPC, T cell precursors or the mature T cells themselves. As already 
described (see 1.1), for myeloid leukaemias there is a growing evidence that they originate in 
haematopoietic stem cells/haematopoietic progenitor cells (HSCs/HPSs) or early myeloid 
progenitors. However,  compared with other mature cell lineages, fully differentiated 
lymphocytes claim a special position in haematopoiesis. They show long life-spans, 
sustained proliferation and the ability of self-renewal. For B cells, it was shown that fully 
mature  B cells can be transformed. However, for mature T cells, several observations 
indicate that these cells are less susceptible to transformation than HSCs/HPCs.  Among 
human haematologic malignancies, mature T cell leukaemias/lymphomas are less frequent, 
which occur predominantly in older patients and have a very poor prognosis. Therefore, to 
further investigate the transformation susceptibility of mature T lymphocytes in comparison 
with HSCs/HPCs, we transduced both of these cell types with the potent T cell oncogenes 
(NPM-ALK and Tax) and the potential oncogene (p21SNFT). Materials  22
2.  Materials
 
Chemicals used in the context of this thesis were obtained from Merck AG (Darmstadt), Roth 
GmbH (Karlsruhe), Santa Cruz Biotechnology Inc. (Heidelberg) and Sigma Aldrich GmbH 
(Hamburg).  
Plastic  material was obtained from Greiner Bio-One GmbH (Frickenhausen), Becton 
Dickinson GmbH (Heidelberg), Thermo Fischer Inc. (Bonn), Costar Inc. (Bodenheim), 
Corning Inc. (Schiphol-Rikjund, The Netherlands), Sarstedt AG & Co (Nürnbrecht) and 
Millipore GmbH (Schwalbach).  
For tissue culture work, media and compounds were obtained from Lonza AG (Basel, 
Switzerland), Invitrogen GmbH (Karlsruhe), PAA Laboratories GmbH (Pasching, Austria) and 
PAN Biotech GmbH (Aidenbach, Austria).  
Escherichia coli TOP10 bacteria and supplies were obtained from Invitrogen GmbH 
(Karlsruhe). Oligonucleotides were obtained from Sigma-Aldrich Genosys GmbH (Hamburg).  
2.1   Buffers, compounds, media and plastic material 
Media and buffers were prepared using deionized water from a Milli-pore filter system 
(Millipore GmbH, Schwalbach). Media were usually autoclaved for 20 minutes at 121°C and 
2 bar pressure, while buffers were sterile filtered. Generally, buffers and compounds were 
stored at room temperature unless stated otherwise.   
Table 2. Buffers, compounds and media for molecular biology 
  Buffer/Compound/Media                            Ingredients/Supplier 
Ampicillin stock solution  100mg/ml Ampicillin (Roth, Karlsruhe) dissolved in dH2O 
Annealing buffer (5x)  0,5M Tris (pH 7,4-7,5), 0,35M MgCl2. 
BW buffer (2x)  10mM Tris (pH 7,5), 1mM EDTA, 2,0M NaCl. 
LB medium  20g LB (Lennox L Broth base) (Invitrogen, Karlsruhe), ad 1l 
dH2O, autoclave 
TAE (50 x)  1220g TRIS-HCl (Roth, Karlsruhe), 285.5g acetic acid (Roth, 
Karlsruhe), 500ml 0.5M EDTA (Roth, Karlsruhe), adjust to pH 
8.0, ad 5l dH2O 
Agarose (1% / 2%)  1g / 2g agarose (Roth, Karlsruhe); ad 100ml dH2O; heat in 
microwave until totally dissolved  Materials  23
Ethidiumbromide (10mg/ml)  BioRad Laboratories (München) 
Working solution: 0.25mg/ml Ehtidiumbromide (125μl 
ethidiumbromie, ad 5ml dH2O) 
DNA loading buffer (6 x)  0.05% bromophenol blue (Serva, Heidelberg), 0.05% xylene 
(Merck, Darmstadt), 15% Ficoll Type 400 (PAA, Pasching, 
Austria), ad 100% dH2O 
Dimethylsulfoxid (DMSO) (7%)  Roth (Karlsruhe) in dH2O 
DNA ladder (100bp / 1kbp)  100μl stock DNA ladder (New England Biolabs, Schwalbach), 
500μl 6 x DNA loading buffer; ad 1.5ml dH2O (store at -20°C) 
LB-Agar ampicillin  32g LB-Agar (Invitrogen, Karlsruhe), ad 1l dH2O, autoclave; 
add 40μg/ml ampicillin before pouring into the plates; (plates 
stored at 4°C) 
Isopropanol  Roth (Karlsruhe) 
Ethanol  Roth (Karlsruhe) 
Bovine serum albumine (100 x)  New England Biolabs (Schwalbach) 
NEB-buffers 1-4  New England Biolabs (Schwalbach) 
dNTPs  New England Biolabs (Schwalbach) 
Oligonucleotides  Sigma Genosys (Deisenhofen) 
LB-ampicillin  20g LB (Lennox L Broth base) (Invitrogen, Karlsruhe), ad 1l 
dH2O, autoclave, add 1ml of 100mg/ml ampicillin (Roth, 
Karlsruhe); (store at 4°C) 
 
Table 3. Buffers, compounds and media for Western blotting 
     Buffer/Compound/Media                        Ingredients/Supplier 
25 x Protease Inhibitor Mix  1 tablet Protease Inhibitor Cocktail
® (Roche, Basel, 
Switzerland); ad 2ml dH2O; (store at 4°C) 
50mM TRIS-HCl washing buffer  Roth (Karlsruhe), adjust pH to 8.0 with HCl 
Acrylamid/Bisacrylamid solution (30%)  Bio-Rad Laboratories GmbH (München); (store at 4°C) 
Ammonuim persulfate (APS) (10%)  10g APS (Merck, Darmstadt); ad 100ml dH2O; (store at 
-20°C) 
Glutaric dialdehyde (25%)  Merck (Darmstadt) 
Glycerol  Merck (Darmstadt) 
HCl  Merck (Darmstadt) Materials  24
Isopropanol  Roth (Karlsruhe) 
Milk in PBST (5%) (MBPST)  5g milk powder (Reformhaus), ad 100ml with PBST; 
(store at 4°C; use at day of preparation) 
Neufeld washing buffer  10mM TRIS-HCl, pH 8.5; 0.6M NaCl, 0.1% SDS, 
0.05% NP40 
NP40 cell lysis buffer  150mM NaCl (Roth, Karlsruhe), 1% NP40 (Merck, 
Darmstadt), 50mM TRIS-HCl, pH 8.0 (Roth, Karlsruhe), 
1mM PMSF (Sigma, Deisenhofen), 1x Protease 
Inhibitor Cocktail® (Roche, Basel, Switzerland); (store 
at 4°C) 
PBS (10x)  Lonza (Basel, Switzerland) 
PBS (1x) 100ml  10x  DPBS  (Dulbecco s phosphate buffered 
saline) (Lonza, Basel, Switzerland); ad 1l dH2O 
PBST (0.1%) 100ml  10x  DPBS  (Dulbecco s phosphate buffered 
saline) (Lonza, Basel, Switzerland), 1 ml Tween®-20 
(Merck, Darmstadt); ad 1l dH2O 
Protein-A agarose (25%, 2 ml)  Santa Cruz (Heidelberg) 
RIPA cell lysis buffer  150mM NaCl (Roth, Karlsruhe), 1% NP40 (Merck, 
Darmstadt), 50mM TRIS-HCl, pH 8.0 (Roth, Karlsruhe), 
0.5% Sodium Deoxycholate (DOC) (Merck, 
Darmstadt), 0.1% SDS (Roth, Karlsruhe), 1mM PMSF 
(Sigma, Deisenhofen), 1x Protease Inhibitor Cocktail® 
(Roche, Basel, Switzerland); (store at 4°C) 
SDS-PAGE running buffer (1 x)  100ml 10 x SDS-PAGE running buffer, 10ml 10% SDS 
solution, ad 1l dH2O 
SDS-PAGE running buffer (10 x)  30.2g TRIS-HCl (Roth, Karlsruhe), 144g glycine (Roth, 
Karlsruhe); adjust pH to 8.8; ad 1l dH2O; (store at 4°C) 
SDS-PAGE sample loading buffer (3x)  300mM TRIS-HCl, 9% SDS; 30% glycerol; 0.05% 
bromophenol blue 
SDS-PAGE separation gel buffer, (1.5 M 
TRIS-HCl, pH 8.8) 
91g TRIS-HCl (Roth, Karlsruhe), adjust pH to 8.8; ad 
500ml dH2O; (store at 4°C) Materials  25
SDS-PAGE stacking gel buffer, (0.5 M 
TRIS-HCl, pH 6.8) 
30.25g TRIS-HCl (Roth, Karlsruhe), adjust pH to 6.8; 
ad 500ml dH2O; (store at 4°C) 
Sodium dodecyl sulfate (SDS) (10%)  10g SDS (Roth, Karlsruhe); ad 100ml dH2O 
Tetramethylethylendiamine (TEMED)  Merck (Darmstadt); (store at 4°C) 
Triton-X 100 lysis buffer  50mM HEPES (pH 7.5), 150mM NaCl, 1% Triton-X 
100, 10% Glycerol, 2mM EDTA, 2% Aprotinin, 1mM 
PMSF, 1x Roche
® Protease Inhibitor Cocktail, 2mM 
Pefabloc
® SC 
Triton-X 100, 10%  10ml Triton-X 100 (Roth, Karlsruhe); ad 100ml dH2O 
Western blot transfer buffer  200ml MeOH (Roth, Karlsruhe); 100ml 10x SDS-PAGE 
running buffer; ad 1l dH2O 
-mercaptoethanol  Roth (Karlsruhe); store at 4°C 
 
Table 4. Buffers, compounds and media for tissue culture 
    Buffer/Compound/Media                          Ingredients (Supplier) 
DMEM (Dulbecco s Modified Eagles 
Medium) 
Containing 4.5g/l Glucose (Lonza, Basel. Switzerland); 
(store at 4°C) 
DMEM-standard medium  500ml DMEM, 5% FCS, 1% penicillin-streptomycin 
(PAA, Pasching, Austria), 2% L-glutamine (PAA, 
Pasching, Austria) 
2.5M Calcium chloride (CaCl2)  Sigma (Deisenhofen); sterile filtered (0.22 μm filter); 
(store at 4°C) 
HEPES (2x, 200mM)  23.83g HEPES (Roth, Karlsruhe); adjust pH 7.00; add 
500ml dH2O; sterile filtered (0.22μm filter); (store at 
4°C) 
Chloroquine (25mM)  Chloroquine (Sigma, Deisenhofen); sterile filtered 
(0.22μm filter); (store at 4°C) 
PBS (Dulbecco s phosphate buffered 
saline) (1 x) 
PAA Laboratories (Pasching, Austria) 
Trypsin (0.25%)   EDTA (1mM)  Invitrogen (Karlsruhe); (store at -20°C) 
RPMI 1640 (Roswell Park Memorial 
Institute 1640) 
Lonza (Basel, Switzerland); (store at 4°C) Materials  26
RPMI-standard medium  10% FCS (PAN Biotech, Aidenbach, Austria), 2%    L-
glutamine (Lonza, Basel, Switzerland), 1% 
Penicillin/Streptomycin (PAA, Pasching, Austria) in 
RPMI 1640 (Lonza, Basel, Switzerland); (store at 4°C) 
Fetal calf serum (FCS)  PAN Biotech (Aidenbach, Austria); (store at   
-20°C) 
Penicillin-Streptomycin (100 x, 10.000U, 
10mg/ml) 
PAA (Pasching, Austria); (store at -20°C) 
2% BSA solution   2 % BSA (in PBS), Invitrogen (Karlsruhe); (store at    -
20°C) 
Hanks balanced salt solution (HBSS)  Sigma, Deisenhofen 
L-glutamine (100 x, 200mM)  PAA (Pasching, Austria); (store at -20°C,  
few weeks at 4°C) 
Mouse interleukin 3 and 6 (IL-3, IL6)  Chiron (Ratingen)  
Mouse stem cell factor  Chiron (Ratingen)  
HEPES (25mM)  Roth (Karlsruhe), adjust with NaOH to pH 7.4; (store at 
-20°C) 
X-Vivo-15 medium  Lonza (Basel, Switzerland); (store at -20°C) 
Human interleukin-2 (IL-2)  
(10000U/ml) 
Novatis (Nürnberg); (store at -20°C) 
Human AB serum (hABS)  Sigma (Deisenhofen); (store at -20°C) 
Pancoll  PAN Biotech (Aidenbach, Austria) 
FACS-buffer  PBS (PAA, Pasching, Austria), 2% FCS and 0.05% 
NaN3, (store at 4°C) 
Retronectin  Invitrogen (Karlsruhe); (store at -20°C, few weeks at 
4°C) 
Anti-CD3-Anti-CD28 Dynabeads
® (1x 
10
8/ml) 
Invitrogen (Karlsruhe) 
Sodium pyruvate (100 x)  Invitrogen (Karlsruhe) 
 
Table 5. Plastic material for tissue culture and molecular biology 
      Plastic material                                  Supplier 
Tissue culture dishes (10cm)  Greiner Bio-One (Frickenhausen) 
Conical polysterene tubes  
(15ml/ 50ml) 
BD (Heidelberg) 
Cryotubes  Sarstedt (Nürnbrecht) 
Reaction tubes (1.5ml, 2ml)  Sarstedt (Nürnbrecht) 
Cell culture flasks (175cm
2, 75cm
2)  BD (Heidelberg) Materials  27
Pipettes (sterile) 
(2ml, 5ml, 10ml, 25ml) 
BD (Heidelberg) 
Tissue culture plates  
(6, 12, 24, 96 well) 
Corning (Schiphol-Rikjund, The Netherlands) 
Non-tissue culture plates (6, 24 well)  Corning (Schiphol-Rikjund, The Netherlands) 
Sterile centrifugation tubes (FACS 
tubes) 
BD (Heidelberg) 
Sterile filter (0.22μm / 0.45μm)  Millipore (Schwalbach) 
Syringe 10ml  Dahlhausen (Köln) 
Non tissue culture plates  BD (Heidelberg) 
Pipette tips (10μl, 200μl, 1000 μl)  Sarstedt (Nürnbrecht) 
 
2.2   Kits 
Table 6. Kits   
                                    Kit                          Supplier 
Annexin V-PE Apoptosis detection kit I for FACS  BD Falcon, Heidelberg 
Calcium Phosphat Transfection Kit  Sigma, Deisenhofen 
Caltag CAL-LYSE
 
Caltag, Hamburg 
DNeasy Blood & Tissue Kit   Qiagen, Hilden 
EasySep Murine SCA1 Selection Kit  StemCell technologies, Kanada 
ECL-Plus Western Blot Kit  Amersham Bioscience, England 
E.N.Z.A. Cycle Pure Kit  peQLab (Erlangen) 
JETquick Plasmid miniprep Spin Kit  Genomed, Löhne 
JETquick Blood DNA Spin Mini Kit  Genomed, Löhne 
Jetquick Gel Extraction Kit  Genomed, Löhne 
Mouse V  TCR Screening Panel for FACS  BD Falcon, Heidelberg Materials  28
 
2.3   Enzymes 
Table 7. Enzymes and standard markers 
                          Enzyme                            Supplier
100bp-Standard marker  New England Biolabs, Frankfurt am Main 
1kb-Standard marker  New England Biolabs, Frankfurt am Main 
Calf Intestine Phosphatase (CIP)  New England Biolabs, Frankfurt am Main 
Restriction enzymes  New England Biolabs, Frankfurt am Main 
Klenow  New England Biolabs, Frankfurt am Main 
Pfx-DNA-Polymerase  Invitrogen, Karlsruhe 
Protein marker for Western-Blot  New England Biolabs, Frankfurt am Main 
Proteinase K  Qiagen, Hilden 
T4 DNA-Ligase  New England Biolabs, Frankfurt am Main 
 
2.4   Oligonucleotides 
Table 8. Oligonucleotides 
       Name                  Primer-Sequencez 5´ 3´       Application 
NPM-ALK_For1  GTCTGAAAATTAGCTCGAC  Sequencing 
NPM-ALK_For2  GCGGCTCTGGCCCAGTGCATATC  Sequencing 
NPM-ALK_For3  GATCTGAAGAGCTTCCTGAG  Sequencing 
Pfu Turbo PCR Amplification  Stratagene, Heidelberg 
Qiagen Plasmid Maxi Kit  Qiagen, Hilden 
QIAquick PCR Purification Kit  Qiagen, Hilden Materials  29
NPM-ALK_For4  GAGGACAGGCCCAACTTCGC  Sequencing 
NPM-ALK_For5  GAAGGCAGCTGCACCGTGC  Sequencing 
NPM-ALK_Rev1  CACACCGGCCTTATTCCAAGC  Sequencing 
NPM-ALK_Rev2  GTTCCTGCTGCCGTGCACCTTG  Sequencing 
NPM-ALK_Rev3  CTTGCTGGGGTAGGGCATG  Sequencing 
NPM-ALK_Rev4  GCTCATCCTGCTCGCTGC  Sequencing 
NPM-ALK_Rev5  GCCTCCACGATGTGCAGCTCGTC  Sequencing 
Tax_For1  CTCCAAGCTCACTTACAGGC  Sequencing 
Tax_For2  CCACGTGATCTTTTGCCACC  Sequencing 
Tax_Rev1  GCTTCGGCCAGTAACGTTAG  Sequencing 
Tax_Rev2  CTGTGGTCAGGCTGATCTTG  Sequencing 
Biotin A1  (biotin) CTG GGG ACC ATC TGT TCT TGG CCC T  LM-PCR 
A2 RV  GCC CTT GAT CTG AAC TTC TC  LM-PCR 
A3 RV  CCA TGC CTT GCA AAA TGG C  LM-PCR 
OC1/FW  GAC CCG GGA GAT CTG AAT TC  LM-PCR 
OC2/FW  AGT GGC ACA GCA GTT AGG  LM-PCR 
Linker 1 FW  GAC CCG GGA GAT CTG AAT TCA GTG GCA CAG 
CAG TTA GG 
LM-PCR 
Linker 2 RV  (phosphate)CCT AAC TGC TGT GCC ACT GAA TTC 
AGA TCT CCC G
LM-PCR 
RASEQ  CTT GCA AAA TGG CGT TAC  LM-PCR 
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2.5   Plasmids 
Table 9. Plasmids  
MHH: Medicine High School Hannover (Medizinische Hochschule Hannover).   
Internal 
Lab.number 
Official name                    Description  Reference/Source 
M187  Eco-env  Expression plasmid for ecotropic 
envelope protein from MLV. 
[44]  
M387  MP91-eGFP  Retroviral vector with optimized MP91-
leader (MPSV-LTR and MESV-vector), 
coding for IRES-eGFP, and a 
packaging signal. 
C. Baum (MHH) and      
D. von Laer 
M579  MLV gag-pol  Expression plasmid for MLV Gag/Pol 
with SV40-Promotor. 
C. Baum (MHH) 
M620  GALV-env  Expression plasmid for ecotropic 
envelope protein from GALV. 
Plasmid factory, 
Bielefeld 
M896 B-Tax M  Cloning plasmid cDNA of viral 
oncoprotein Tax M. 
GENEART 
M899 B-NPM-ALK  Cloning plasmid cDNA of human 
fusion oncogene NPM-ALK. 
GENEART 
M900 B-  P21SNFT  Cloning plasmid cDNA of human 
P21SNFT. 
GENEART 
M905  MP91-Tax M  Retroviral vector with optimized MP91-
leader (MPSV-LTR and MESV-vector), 
coding for Tax M-IRES-eGFP, carrying 
a packaging signal. 
Cloned in this work. 
M906  MP91-NPM-ALK  Retroviral vector with optimized MP91-
leader (MPSV-LTR and MESV-vector), 
coding for NPM-ALK-IRES-GFP, 
carrying a packaging signal. 
Cloned in this work. 
M907  MP91- P21SNFT  Retroviral vector with optimized MP91-
leader (MPSV-LTR and MESV-vector), 
coding for P21SNFT-IRES-eGFP, 
carrying a packaging signal. 
Cloned in this work. 
pCR 2.1-
TOPO 
pCR 2.1 TOPO  Cloning plasmid for sequencing.    Invitrogen Materials  31
2.6   Antibodies 
Table 10. Antibodies 
     Primary antibodies (clone)             Marker       Supplier  Application 
Hamster- -Mouse CD3 (145-2C11)  -  BD  Stimulation 
Hamster- -Mouse CD3 (145-2C11)  R-Phycoerythrin-Cy5  Invitrogen  FACS 
Rat- -Mouse CD4 (RM4-5)  R-Phycoerythrin-Cy5.5  Invitrogen  FACS 
Rat- -Mouse CD8a (CT-CD8a)  R-Phycoerythrin  Invitrogen  FACS 
Mouse- -Mouse CD11b (M1/A70)  Allophycocyanin  BD  FACS 
Rat- -Mouse CD19 (6D5)  R-Phycoerythrin-Cy5.5  Invitrogen  FACS 
Hamster- -Mouse CD28 (37.51)  -  BD  Stimulation 
Mouse- -Mouse CD45.1 (A20)  R-Phycoerythrin  BD  FACS 
Mouse- -Mouse CD45.2 (104)  PerCP-Cy5.5  BD  FACS 
Hamster- -Mouse TCR  (H57-597)  Allophycocyanin  BD  FACS 
Mouse IgG1- -Mouse Pre-alpha-TCR  -  BD  FACS 
Mouse- -Mouse NK1.1  Allophycocyanin  BD  FACS 
Fc-Block- -Mouse CD16/CD32 
(2,4G2) 
-  BD F ACS-block 
Rabbit- -ALK  -  abcam  Western-blot 
Mouse- -P21SNFT  -  Abnova  Western-blot 
Mouse- -HTLV-I Tax  -  abcam  Western-blot 
Secondary antibodies/Reagents             Marker       Supplier  Application 
Streptavidin  Allophycocyanin  BD  FACS 
Rat- -Mouse IgG1  Biotin  BD  FACS 
Goat- -Rat-IgG  PE  Invitrogen  FACS Materials  32
Goat- -Hamster-IgG  PE  Invitrogen  FACS 
Goat- -Mouse-IgG  Allophycocyanin  Invitrogen  FACS 
Goat- -Rabbit  HRPO  Santa Cruz Biot.  Western blot 
Streptavidin  HRPO  Santa Cruz Biot.  Western blot 
 
2.7   Bacteria 
Molecular biology work was performed with E. coli TOP10 supplied by Invitrogen (Karlsruhe). 
The genotype of E. coli TOP_10 is: F
- mcrA  (mmr-hsdRMS-mcrBC)  80lacZ M15  lacX74 
deoR recA1 araD139  (araleu)7697 galK rpsL (Str
R) endA1 nupG.  
2.8   Cell lines and primary cells 
Table 11. Cell lines and primary murine cells 
              Cell line/Primary cells                     Description/Medium 
293T  Human embryonic kidney epithelial cells 
transduced with T-antigen of SV40 [45]. For 
packaging of constructs.                                              
DMEM-standard 
SC-1   Murine Fibroblast cell line [46]. For Titration of 
produced retroviral (Eco env) supernatant.                 
DMEM-standard.                                                    
TE671  Human medulloblastoma cell line [47]. For Titration 
of produced retroviral (GALV env) supernatant.          
DMEM-standard.                                         
PM-1  Human T cell line originating from HUT 78 cell line, 
expressing CCR5 and CXCR4 [48]                             
RPMI standard. 
Jurkat, clone E6-1  Human T cell line, a clone of the Jurkat-FHCRC 
cell line.                                                         Materials  33
RPMI-standard. 
Primary T lymphocytes  Isolated from spleen and lymph nodes of  C57BL/6 
Ly5.1 or OT-I donor mice.                                       
Mouse medium special: RPMI 1640 with 10% 
FCS, 2% Glutamine, 1 % Pen/ Strep, Sodium 
Pyruvat (1x), NEAA (1x) and  -Mercaptoethanol 
(1x) + 100U/ml IL-2.   
Primary lineage negative stem cells  Isolated from the bone marrow of six to eight weeks 
old C57BL/6 Ly5.1 donor mice.                               
RPMI with 10% FCS, 50ng/ml mSCF, 10ng/ml 
mIL-3, 50ng/ml mIL-6. 
 
2.9   Instruments/Equipments 
Table 12. Instruments/Equipments 
                            Instrument                       Supplier
Analytical scales  Kern & Sohn (Balingen-Frommern) 
Autoclave HST 4-5-6 E  Zirbus Techonolgy (Bad Grund) 
BIOBEAM 2000 Cs-137 (Radiation source + 
accessoriy)
Eckert & Ziegler, Berlin 
Incubator  Heraeus, Hanau 
Cell Counter Casy Tone TT  Schärfe Systems (Reutlingen) 
Centrifuge (cooled) Avanti J20  Beckman (München) 
Centrifuge (cooled) Rotina 48R  Hettich (Tuttlingen) 
Clean bench HERAsafe HS12  Heraeus (Hanau) 
DNA-electrophoresis-chamber  BioRad (München) 
DNA-Sequencer  Applied Biosystems (Weiterstadt) 
EasySep Magnet  StemCell technologies, Canada 
FACScan  Beckton Dickinson (Heidelberg) Materials  34
Film developing machine Optimax Type 1R  Schroeder und Henke (Wiesloch) 
Fluorescent microscop Eclipse TE300  Nikon, Düsseldorf 
Heating block DRI-BLOCK BD 2D  Techne (England) 
Incubator for molecular biology  Heraeus (Hanau) 
Incubator for tissue culture  Heraeus (Hanau) 
Magnetic stirrer  IKA (Staufen) 
Microscope  Leica (Bensheim) 
Nano-Drop spectrometer  Peq-Lab (Erlangen) 
PCR-Cycler  Biometra (Göttingen) 
pH-meter Toledo MP 220  Mettler (Gießen) 
Pipetboy acu  Intergra Biosciences (Fernwald) 
Pipettes   Gilson (USA) 
Scil Vet ABC (Animal Blood Counter)  Scil animal care company, Viernheim 
Shaking incubator TH25  Edmund Bühler (Tübingen) 
Swinging bucket centrifuge Megafuge 1.0R  Heraeus (Hanau) 
Table top centrifuge Megafuge 1.0R  Heraeus (Hanau) 
Typhoon Phosphor Imager  GE (Freiburg) 
UV transluminator GelDoc 2000   BioRad (München) 
Vortex Genie 2   Bender und Hobein (Switzerland) 
Water bath  GFL (Burgwedel) 
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2.10     Materials for animal experiments 
2.10.1  Mouse strains and husbandry conditions 
Six to eight week old C57BL/6J.Ly5.1 (CD45.1+) and C57BL/6J.Ly5.2 (CD45.2+) RAG-1 
deficient mice were obtained from Charles River laboratories (Sulzfeld, Germany) and 
Jackson laboratory (Bar Harbor, USA). Animals were bred and maintained under specific 
pathogen-free (SPF) like conditions in the animal facilities of the Georg-Speyer-Haus. Cages 
were individually ventilated (IVC). Symptomatic/leukaemic or healthy animals (donors) were 
sacrificed  after anesthesia by cervical dislocation and examined for pathological 
abnormalities, including histology, morphology, white blood counts (WBC) and flow 
cytometry. The experiments were performed in compliance with the local animal 
experimentation guidelines. Animal experiments were approved by the regional council 
(Regierungspräsidium) Darmstadt, Hessen, Germany.  
Tabel 13. Mouse strains 
           Name/Reference       Internal name                Supplier 
B6.SJL- Ptprc
a Pep3
b/BoyJ [49]   Ly5.1  Charles River Laboratories 
Jaxmice, USA 
B6.129S7-Rag-1
tm1Mom/J [50]   Rag-1  Charles River Laboratories 
Jaxmice, USA 
C57BL/6Tg (TcraTcrb) 1100Mjb/j 
[51] 
OT-I  Charles River Laboratories 
Jaxmice, USA 
 
 
T lymphocytes or lineage negative stem cells were isolated from OT-I or Ly5.1 donor mice.  
Rag-1 deficient mice do not have any T and B lymphocytes and served as receiver animals. 
Ly5.1 haematopoietic cells could be differentiated by the antigen CD45.1 from the Rag-1 
recipient (background C57BL/6 Ly5.2) cells having CD45.2 cells.  
Transgenic OT-I mice possess only one type of exogenous TCR in the context of H2Kb 
(MHC-I) specifically directed against an epitope (amino acid residues 257-264) of Ovalbumin 
(OVA). Due to MHC-I context, almost exclusively cytotoxic T lymphocytes (CD8+) are 
generated in these animals. The donor cells were used as monoclonal T cell population. 
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2.10.2  Animal-experiment materials  
Table 14. Animal-experiment materials and their applications 
            Materials                 Application                Supplier 
Ear hole puncher (Napox)  Marking of laboratory animals  Heiland, Hamburg 
Histosette  Organ embedding  Simport, Canada 
Microvette (EDTA-coated)  Blood taking  Sarstedt, Nümbrecht 
Corktray (Hebu)  Dissection   Heiland, Hamburg 
Insulin syringe   Intravenous transplantation  BD, Heidelberg 
Cell strainer (100μm)  Homogenization of organs and 
filtration of cell suspension 
BD, Heidelberg 
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3.  Methods
 
3.1   Molecular Biology 
3.1.1 DNA digestion with restriction enzymes 
For the cloning or subcloning of plasmids and restriction analyses, plasmid DNA was 
digested with restriction endonucleases. Restriction enzymes were obtained from New 
England Biolabs and used in the recommended 10x buffers. For a preparative digestion 2-
4μg of plasmid DNA was incubated for 1 to 12 hours with 5 to 20 units of restriction 
endonuclease in 35μl total sample volume. The digest was monitored by agarose gel 
electrophoresis (see section 3.1.3). For subcloning, bands were isolated from the gel and 
treated as described in section 3.1.4. For restriction analysis, 0.5 to 1μg plasmid DNA was 
digested in 20μl sample volume with 5 to 10 units restriction enzyme for 1 to 2 hours. 
Digestion was monitored by agarose gel electrophoresis.  
 
3.1.2 Dephosphorylation of DNA fragments at the 5 end 
Before ligation with insert, digested linearized vector plasmid was dephosphorilated to 
prevent religation. For this purpose, 1 μl (10 units) of calf intestinal phosphatase (CIP) was 
added to the restriction digest and incubated for 45 to 60 minutes at 37°C. Thereafter, the 
digested plasmids were run on the agarose gel to isolate the required fragments for ligation.  
 
3.1.3 Agarose gel electrophoresis 
The separation of double stranded DNA fragments was performed in a horizontal agarose gel 
in 1x TAE buffer. Generally, 1% agarose gel was used for separation. Smaller fragments 
(<500bp) were separated in 2% agarose gels. The agarose powder was dissolved in 1x TAE 
by heating in a microwave. Ethidiumbromide (1%) was added in a 1/1000 dilution before 
pouring the agarose into a gel-casting chamber. The polymerized agarose was placed in an 
electrophoresis chamber filled with 1x TAE. The DNA samples were mixed with 6x DNA 
loading buffer and pipetted into gel slots. As size markers, 10 to 12μl (~400ng) 100bp and 
1kbp ladder (NEB) were loaded onto the gel. Electrophoresis was performed at 100V for 30 
to 40 minutes. The gel was placed onto a UV transilluminator and scanned in a BioRad® 
Geldoc 2000®. The appropriate fragments were cut out.  Methods  38
3.1.4 Isolation of DNA fragments from agarose gels 
For the isolation of DNA fragments the required fragments were cut out of the agarose gel 
with a scalpel and transferred into an Eppendorf reaction tube. New scalpel was used for 
each fragment. The extraction of DNA was performed with a JETquick gel extraction kit 
according to the manufacturer s instructions. 
 
3.1.5 Ligation of DNA 
The covalent ligation of DNA fragments was performed with the Quick-ligase®. The ligation 
was performed out in a total volume of 20μl with approximately 200ng linearized, 
dephosphorylated plasmid DNA and a three-fold excess of the insert for 15-20 minutes at 
room temperature. 10 units of Quick-ligase® (1μl) were added and the provided 2x Quick-
ligase® buffer was used. The ligation mixture and a control sample without insert were used 
to transform competent E. coli TOP10® bacteria.  
 
3.1.6 Transformation of Escherichia coli with plasmid DNA 
Ligation products were transformed into E. coli TOP 10 bacteria. 50μl of competent bacteria 
were thawed and mixed with 20μl ligation samples. Cells were incubated on ice for 30 
minutes and subsequently heat shocked for 2 minutes at 42°C. This heat shock leads to the 
uptake of DNA into competent cells. Subsequently, cells were cooled on ice for two minutes. 
500μl LB medium was added and cells were incubated at 37°C for 45 minutes in a shaking 
incubator.  Afterwards, cells were pelleted and supernatant was removed. Pellets were 
carefully resuspended in 50μl LB medium and cell suspensions were plated on an ampicillin 
(amp) supplemented LB-agar dish. After over night incubation at 37°C, the bacterial colonies 
were picked and used to inoculate mini DNA preparations (see section 3.1.8).  
 
3.1.7 Preparing competent Escherichia coli for transformation 
For transformation of ligation products, competent E. coli bacteria were prepared as follows: 
2ml of E. coli TOP10 over night culture was mixed with 200ml of LB-medium and incubated 
until the culture reached an OD (optical density) of 0.5 to 0.7. The bacterial suspension was 
transferred into 50ml Falcon tubes and incubated for 10 minutes on ice. Afterwards, the 
Bacteria were harvested via centrifugation at 2890xg, 4°C for 10 minutes. Pellets were 
resuspended in 40ml of ice-cold 0.1M MgCl2  solution. Afterwards, cells were pelleted, the 
supernatant was discarded and cells were resuspended in 20ml of 50mM CaCl2  solution. Methods  39
After 30 minutes incubation on ice, bacteria were pelleted again and resuspended in 2ml of 
50mM CaCl2-15% glycerol solution. Aliquots of 200μl were prepared and shock-frozen in 
liquid nitrogen and subsequently stored at -80°C. The competence was measured for 1x 10
6 
colonies for 1μg plasmid DNA. The competent cells were prepared by Tefik Merovci, AG von 
Laer. 
 
3.1.8 Preparations of DNA plasmid from Escherichia coli 
Small-scale plasmid DNA preparations for analytic purposes were done using the peqGOLD 
Plasmid Miniprep Kit I. 3ml of an overnight culture of transformed E. coli TOP_10 bacteria 
was used according to manufacturers
 
instructions. The typical plasmid DNA yield was in-
between 5-10μg in a total volume of 50-100μl elution buffer.  
For preparative purposes. maxi preparations were performed using a total bacterial culture 
volume of 250ml. Maxi preparations were performed using the Nucleobond AX PC500 
Maxiprep Kit, yielding plasmid DNA amounts in-between 0.5-1.5mg. Plasmid DNA 
concentrations were adjusted to 1mg/ml and stored in 200μl working aliquots at -20°C. All 
plasmid DNA concentrations were determined using a Nanodrop  1000 spectrophotometer. 
 
3.1.9 Culture conditions and preservation of Escherichia coli 
After transformation, plasmid-containing E. coli bacteria were cultured in ampicillin 
supplemented LB-medium (100μg/ml). Single clone colonies were produced by plating E. coli 
bacteria on LB-agar and incubating at 37°C for 12 to 16 hours. Agar plates were stored at 
4°C and used for inoculation of mini and maxi preparations for several weeks. For cryo stock 
preparation, E. coli bacteria were cultured over night in a 37°C shaking incubator. 500μl of 
the culture was mixed with 500μl 7% DMSO in H2O and stored at -80°C. Fresh cultures were 
inoculated by scratching a little amount of bacteria out of the cryo tube and transferring into 
LB-ampicillin medium. 
 
3.1.10  Sequencing of DNA preparations 
DNA sequencing was performed in the sequencing core facility of Georg-Speyer-Haus using 
a 3100 Avant Genetic Analyzer (Sanger procedure). For sequencing, 10μl mini DNA aliquot 
was mixed with 1μl of 10μM oligonucleotide solution and water was added to a total volume 
of 16μl. 0.5μg maxi preparation DNA was used in 16μl total sample volume, containing 1μl 
oligonucleotide solution.  Methods  40
3.1.11  LM-PCR and integration site analysis 
In order to determine the integration site of the retroviral provirus in the host genome, the 
flanking sequences have to be identified. LM-PCR (ligation mediated PCR) is a very powerful 
method [52] for the amplification of DNA fragments whose sequences are partially known. 
For this purpose, the DNA was first isolated from the cell suspensions or tumors using 
DNeasy Blood & Tissue Kit and then digested with the restriction enzyme Tsp509I. This 
enzyme recognizes and digests palindromic sequences with AATT nucleotide sequence and 
produces sticky ends. Digestion occurs three times in the proviral sequence - once in the 5' 
and the 3' LTR sequence and once between them as well as several times in the host 
genome. Afterwards, the strand extension (primer extension) is performed in a one-step-
PCR, creating single stranded DNA with a biotin molecule, which can be isolated by 
paramagnetic-Streptavidin coated particles (Dyna beads). Finally, for every integration site, 
two fragments are cleaned up, one fragment containing the 3´LTR and part of the proviral 
sequence (internal control band); and the other containing the 5´LTR and a part of the 
unknown host genome sequence (external band), (after trimming the external band, this 
sequence is aligned or compared to the whole genome). Thereafter, an adapter cassette 
(Linker) is ligated to the end of the unknown host DNA fragments as well as to the internal 
band (Adapter Ligation). The following steps are for a PCR and a  nested PCR. 
For the PCR, two oligonucleotides (primers) are used, one complementary to the adapter 
(OC1/FW), and the other complementary to the known part of the LTR sequence (A2RV). In 
order to achieve a higher sensitivity and a stronger amplification of the target sequence, a 
nested PCR  with  the  oligonucleotides  OC2/FW  and A3RV is performed. Both primers bind 
inward compared to the PCR primers. With this method, the target sequence is amplified first 
in a standard PCR (external PCR) and subsequently, a part of this reaction is used as a 
template for the  nested  PCR (internal PCR). The procedure in the available work was 
adapted according to Schmidt et al [53] and is schematically represented in figure 9. After 
nested PCR,  products  are  isolated  from  a  2%  agarose gel. In each case, the individual 
fragment was cut out with a new scalpel to prevent contamination with other fragments. The 
DNA was then eluted by gel purification as described in 3.1.4. Afterwards, the eluted DNA 
was sequenced directly with the oligonucleotide A3RV. Since this did not work in every case, 
DNA fragments were subcloned into TOPO-vector pCR2.1 (Invitrogen). After following the 
manufacturers  instructions, the ligation proceeded for 30-45min. The transformation was 
done into chemically competent E.coli TOP10-cells (see section 3.1.6). On the next day, 8 
positive white clones (per subcloned DNA fragment) were picked for a Colony PCR. The 
amplification of the fragments took place with the oligonucleotide pair OC2/FW + A3RV or 
M13for(-40) + M13rev. Part of the PCR product was analyzed on a 2% agarose gel and the 
correctly amplified PCR products were cleaned up by Sodium-Acetate/Ethanol precipitation Methods  41
and then sequenced. The sequencing took place with the oligonucleotide A3RV and/or 
M13for(-20).   
    
                
                                       
                  Figure 9. Individual steps of ligation mediated PCR.  
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The sequencing results were trimmed by the program  LASERGENE® v8.0 SeqMan to 
obtain the flanking genomic sequence, which could be compared to the mouse genome 
(NCBI 37).  The individual steps of the LM-PCR are described more accurately in the 
following procedure:   
1. Restriction of the genomic DNA 
For this, 0.25-1μg of cleaned-up genomic DNA and the enzyme Tsp509I were used. 
According to standard, 500ng DNA was used in a total volume of 30μl. The buffer, indicated 
by the manufacturer was used and the incubation period was kept up to 2h at 65°C. After 
digestion, the DNA was purified by using the  MinElute Reaction CleanUp Kit' (Qiagen). After 
following the manufacturers  instructions, the DNA was eluted with 10μl Elution buffer.  
2. Strand extension (Primer extension) 
This step was performed with the  Phusion® High-Fidelity DNA-polymerase enzyme and the 
oligonucleotide  Biotin A1 .  
Table 15. Composition of the primer extension reaction           
Table16. Incubation program for primer extension reaction         
15μl  DNA 
5μl  5x Phusion buffer 
1μl  5mM dNTP 
1μl  Primer Biotin A1 (0.25 pmol/μl ) 
1μl  Phusion DNA Polymerase 
2μl H 2O 
Step  Temperature (°C)  Duration (Min.) 
1  95 5 
2  65  30 
3  72  15 
        4 4                                      
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After this step, the DNA was cleaned up using the  MinElute Reaction CleanUp Kit (Qiagen). 
After following the manufacturers  instructions, the DNA was eluted twice with 20μl Elution 
buffer. 
 
3. Biotin-Streptavidin interaction  
20μl (corresponding to 200μg) of Streptavidin conjugated Dyna-Beads per sample were 
used. The beads were washed twice with 100μl 2xBW buffer and resuspended in 40μl of 
2xBW buffer in a 2ml reaction tube. Now, 40μl DNA was added to the 40μl prepared beads. 
The mixture was incubated for 1h on the shaking-rotator with ~1000 rpm at room temperature 
(25°C). Subsequently after two times washing with H2O, the DNA Bead-conjugate was 
resuspended in 5μl H2O. 
 
4. Ligation of Linker cassette 
In each sample of resuspended 5μl DNA bead-conjugate, the following ligation preparations 
were added: 
 
 
Table 17. Composition of ligation preparation 
5μl  DNA-bead-conjugate 
0,2μl  T4 Ligase 
2μl  10x Ligation-buffer 
1μl  Polylinker 
11,8μl H 2O 
 
 
The ligation reaction was incubated over night at 16°C in the shaking-incubator with ~1100 
rpm (2min. on / 5min. off). Subsequently, this reaction was washed twice with 100μl H2O and 
resuspended in 10μl H2O.  
The Polylinker was assembled as follows: 40μl H2O and each 20μl of Linker1FW 
(200pmol/μl) and Linker2RV (200pmol/μl) was incubated for 5 min at 70°C in the water bath 
and afterwards 20μl of 5x Annealing buffer was added. A further incubation for 5min at 70°C 
in the water bath was followed. Subsequently, the water bath was switched off and the Methods  44
samples slowly cooled down over night. Afterwards, 10μl aliquots were made and kept at       
-20°C. The aliquots were used only once.  
 
 
5+6. LM-PCR and nested PCR  
Both, the actual LM-PCR and the following  nested  PCR were performed with the  Extensor 
Hi-Fidelity Kit  (ABgene). Both reactions have the same composition and the same PCR 
program except for the oligonucleotides. After the LM-PCR the reaction product was diluted 
to 1:50 with H2O and used in the nested PCR. 
 
Table 18. Composition of LM-PCR and nested PCR 
1μl  DNA-bead-conjugate and/or LM-PCR-product (1:50) 
12,5μl  Extensor Hi-Fidelity PCR Master Mix 
1μl  OC1/FW (25pmol/μl) and/or OC2/FW (25pmol/μl) 
1μl  A2RV (25pmol/μl) and/or A3RV (25pmol/μl) 
9,5μl H 2O 
 
 
Table 19. PCR Program for LM-PCR and nested PCR 
Step  Temperature(°C)  Duration (sec) 
 
 
1  94  120   
2  94  15  
3  60  30   
4  68  120  To step 2, 30 cycles 
5  68  600   
6 4   
 
 
 
 
 
After running on a 2% agarose gel, the remarkable fragments were cut out and either directly 
sequenced with A3RV-oligonucleotide or subcloned into the TOPO-vector pCR 2.1. Methods  45
Subsequently after sequencing, the integration site analysis (already mentioned)  was 
performed. In case of the subcloning (already mentioned), a Colony PCR was performed 
after picking the positive, white E.coli colonies. For this, a picked clone was directly used in a 
50μl PCR reaction mix and incubated for 10min. The following PCR begins with a long step 
of 10min at 94°C, in which the bacteria are lysed and the plasmid DNA is set free. The TOPO 
vector with ligated  Insert from  the  mouse  genome and the oligonucleotide of the PCR come 
into contact.  
 
Table 20. Composition of Colony PCR 
1 μl  10μM M13 rev bzw. A3RV 
1 μl  10μM M13 for (-40) bzw. OC2/FW 
1 μl 10  mM  dNTP s 
5 μl  15mM buffer (+MgCl2) 
0.3 μl  5 U/μl Taq-Polymerase 
41,7 μl H 2O 
 
 
Table 21. PCR program for Colony PCR 
Step  Temperature (°C)  Duration (sec.)
 
1  94  600  
2  94  30  
3  53  30  
4  72  60  To step 2, 27 cycles 
5  72  300  
6 4 
 
 
 
Further procedure for cleaning up of the PCR products and the sequencing has already been 
described. Methods  46
3.1.12  Western blotting 
Western blotting was performed to monitor the transgene expression. For that reason, 
transfected 293T cells (see section 3.2.3.1) or transduced SC-1 cells (see section 3.2.3.2) 
were used two days after transfection/transduction. The cells were split via trypsination as 
follows: 
The cells were washed once with ~3ml 1xPBS. After aspiration of the PBS, 1ml trypsin was 
added to the cells for  ~30 seconds. Trypsin was inactivated by addition of 4ml DMEM-
standard medium. Cells were resuspended using a 5ml-pipette and counted using the Casy 
cell counter.  
3x10
6 cells were transferred to 2ml reaction tube and centrifuged for 2 minutes at 13000rpm. 
Afterwards, the cell pellets were washed with 1ml cold sterile 1xPBS. The cell pellets were 
resuspended in 80 l ice-cold lysis buffer and vortexed and incubated for 15 minutes on ice. 
The lysates were then spinnned down for 10 minutes at 13000rpm in a microcentrifuge (4°C) 
to settle the cell debris down. Proteins in the supernatant were harvested. Afterwards, the 
supernatant was transferred to a fresh 1.5ml reaction tube and 3x protein loading buffer was 
added to obtain a final loading buffer concentration of 1x. This was then heated for 5 minutes 
at 97°C in a heat block, and then stored at -20°C until further use.   
3.1.12.1 Sodium dodecyl sulfate polyacrylamide gel electrophoresis  
Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) is a denaturing 
separation method that separates the proteins according to their molecular size in an 
electrical field irrespective of their structure and net charge. Denaturing conditions are 
achieved by addition of the anionic detergent sodium dodecyl sulfate (SDS) to the protein 
samples. SDS mainly binds to the hydrophobic amino acids of proteins, thereby applies 
negative charge to each protein in proportion to its mass. Furthermore, the dodecyl sulfate 
anion compensates the proteins
 
own charges giving every protein a highly negative net 
charge. These two effects allow the separation of proteins based solely on protein size. SDS-
PAGE is mostly a discontinuous electrophoretic method meaning that two types of 
polyacrylamide gels are casted. The lower separation gel has an alkaline pH value (8.8) and 
a polyacrylamide concentration ranging from 9 to 16%. The concentration of polyacrylamide 
directly determines the mesh size of the matrix, which should be adapted to the molecular 
weight of the protein of interest. The stacking gel is laid upon the separation gel and has a 
neutral pH value of 6.8 and a low polyacrylamide concentration leading to a wide matrix 
meshwork. In the discontinuous SDS-PAGE, the separation of proteins respective to their 
size takes place in the alkaline separation gel. The neutral stacking gel serves to focus the 
proteins in each lane to a small band at the interphase between stacking and separation gel. Methods  47
This is necessary, because all proteins must enter the separation gel at the same time to 
obtain sharp protein bands. This is achieved by the high glycine concentration in the gel and 
the running buffer. Glycine is the smallest amino acid and has a pH of  6.0. At the pH of the 
stacking gel, it is minimally negatively charged and mainly exists in its zwitterionic form. 
Therefore, the glycine ions are the speed-limiting factor of current flow in the stacking gel, 
which leads to a protein band focusing. In the separation gel, the glycine ions are anionic and 
proteins are separated by running at their respective speeds. The two gels were prepared 
according to the following table.   
Table 22. Reagents for SDS-PAGE, stacking gels (4%) and resolving gels (10/16%) 
Gel 
percentage 
ddH2O 
[ml] 
30% degassed acrylamide-
bisacrylamide solution [ml] 
Gel buffer 
[ml] 
10% SDS 
(w/v) [ml] 
4%  6.1  1.3  2.5
1  0.1 
10%  4.1  3.3  2.5
2  0.1 
16%  2.1  5.3  2.5
2  0.1 
1Stacking gel: 0.5 M TRIS-HCl, pH 6.8 
2Resolving gel: 1.5 M TRIS-HCl, pH 8.8  
The polymerization was initiated by addition of 50μl 10% ammonium persulfate and 5μl 
TEMED to the 10ml gel solutions (for the stacking gel 10μl TEMED were added). Gels were 
generally prepared with a BioRad Mini Protean III system. The separation gel solution was 
pipetted between the two glass plates fixed onto the casting stand. Isopropanol was layered 
on top of the gel to obtain a smooth phase transition. The gel was allowed to polymerize for 
30 to 40 minutes. The isopropanol was removed and the top of the separation gel was rinsed 
with deionized water. APS and TEMED were added to the prepared stacking gel solution and 
poured onto the separation gel. The comb was inserted and the gel was allowed to 
polymerize for 40 to 50 minutes. Polymerized gels were wrapped in wet tissue papers and 
stored at 4°C until use.   
3.1.12.2 Immunoblotting 
Immunoblotting allows the specific detection of proteins following their separation via SDS-
PAGE. For this, the separated proteins are immobilized on a membrane and are detected by 
specific antibodies, which are directed against the protein of interest. Secondary antibodies 
that are chemically coupled to a reporter system, such as the horseradish peroxidase, in turn Methods  48
bind to the primary antibodies. The signals produced by the reporter system can then be 
detected. The respective dilutions for the used antibodies are summarized in table 23: 
 
Tabel 23. Dilutions for the Western blot antibodies 
Primary antibody  Marker  Dilution (5% milk in PBST) 
Rabbit- -Alk   -  1:400 
Mouse- -p21SNFT  -  1:2000 
Mouse- -HTLV I Tax  -  1:400 
Secondary 
antibody/Reagent   
Goat- -rabbit  HRPO  1:10000 
Goat- -mouse  HRPO  1:10000 
 
 
 
Molecular sizes of detected proteins were calculated by referring to a marked protein ladder 
(10-250 kDa) from New England Biolabs (Ipswich USA), run in parallel on each gel. Here, the 
protein transfer onto the nitrocellulose membrane was performed by the semi-dry approach. 
The blot was assembled as follows: 
 
1. Whatman paper, soaked in transfer buffer 
2. Membrane 
3. Poly-acryl amide gel 
4. Whatman paper, soaked in transfer buffer  
The membrane and the Whatman papers were cut to the size of the gel. Air bubbles were 
removed from the blot and transfer was performed for 30 to 45 minutes at 15 volts. The blot 
was disassembled and the primary antibody was applied at appropriate concentrations over 
night at 4°C in 5% milk in PBST (MPBST). On the next day, primary antibody was discarded 
and the membrane was washed three times for 10 minutes with 20ml PBST. The secondary 
antibody was applied at appropriate concentrations in MPBST for 2 hours at room 
temperature. The antibody solution was discarded and the membrane was washed again 
three times for 10 minutes with PBST. For the development of the blot, ECL® or ECL plus® Methods  49
kit from Amersham Bioscience® was used. For this, the two provided substrates were mixed 
1:1 or 40:1, respectively. Blots were incubated 5 minutes with the mixed substrate in the 
dark. After removing excess substrate from the membrane, it was then placed into a plastic 
foil and then transferred into an Amersham Hypercassette®. Hyperfilm ECL® photo films 
were applied under safelight conditions to the blots for various exposure times and the films 
were developed in the film developing machine. 
 
3.2   Tissue culture Culture conditions for eukaryotic cell lines  
The cell lines used during this work were adherent (293T) and suspension (PM-1 and Jurkat). 
293T cells were cultured in DMEM containing 10% fetal calf serum (DMEM-standard). 
1.5x10
7 293T cells were seeded in a 175cm
2 cell culture flask. Cells were split every 3 to 4 
days via trypsination as follows: 293T cells were washed once with 20ml 1xPBS. After 
aspiration of the PBS, 5ml trypsin was added to the cells and left for half to 1 minute. Trypsin 
was then inactivated by addition of 25ml DMEM-standard medium. Cells were resuspended 
using a ten-milliliter-pipette. The separation of cells was monitored under the microscope. 
Cells were counted using the Casy cell counter.  
PM-1 and Jurkat cells were cultured in RPMI supplemented with 2% glutamine, 5% FCS and 
1% Pen/Strep (RPMI-standard). Cells were split after every 3 to 4 days at a 1:3 ratio and 
12ml fresh RPMI-standard medium was added in a 75cm
2  cell culture flask. For cell 
expansion, 6ml of PM-1/Jurkat cell suspension (containing 9x10
6 cells) was added to a total 
volume of 50ml RPMI-standard in a 175cm
2  cell culture flask. Cells were harvested at a 
density of 1.5x10
6 cells per ml (3-4 days after seeding).   
3.2.1 Freezing and thawing of cells 
For long-term storage, cells were kept in liquid nitrogen. The cultured suspension cells were 
counted. Adherent cells were trypsinized, diluted in excess of complete culture medium and 
counted. The cell suspensions were then transferred to a 50ml Falcon tube and pelleted by 
centrifugation for 10 minutes at 1200rpm and 4°C. The supernatants were discarded and the 
cell pellets were resuspended in 90% FCS, 10% DMSO at a concentration of 10
7  cells/ml. 
1ml aliquots of the cell suspensions were transferred to cryotubes in a pre-cooled ( 4°C) 
freezing container and were incubated at -80°C overnight before the cryotubes were stored in 
liquid nitrogen. 
To restore cryo-stocks of cells, cells were thawed rapidly in a waterbath at 37°C. The cell 
suspension was diluted in 12ml pre-warmed medium in a 15ml Falcon tube and centrifuged 
for 5 minutes at 1200rpm. The DMSO-containing supernatant was discarded and the cell Methods  50
pellet was resuspended using 12ml of complete medium. Finally, the cell suspension was 
transferred into a T-75 cell culture flask and cultured at 37°C.  
3.2.2 Isolation and stimulation of primary murine MNCs/HSCs 
3.2.2.1   Isolation of primary murine MNCs 
Murine MNCs (mononuclear cells) were isolated from WT-mice (Ly5.1 or OT-I mice). After 
sacrificing the mice by breaking the nape, skin was disinfected with 70% EtOH. Spleen and 
lymph nodes (mesenteric and superficial inguinal) were removed and transferred into a 50ml 
Falcon tube containing 10-20ml ice-cold 1xPBS. Spleen and lymph nodes with the whole 
volume of PBS were homogenized with a syringe stamp through the screen cup in a 10cm 
tissue culture dish to get a single cell suspension.  The whole volume of single cell 
suspension was filtrated through a cell strainer into a new 50ml tube. The dish was washed 
twice with 10ml PBS and the washing solutions were filtrated through the same cell strainer 
into the same 50ml tube. Cells were centrifuged for 10min. at 360RCF and room 
temperature. Supernatant was removed and cell pellet was resuspended with 10ml PBS. The 
removed supernatant was centrifuged again. This time supernatant was discarded. The 
second cell pellet was resuspended with 10ml PBS. Both cell suspensions were combined in 
one tube to get a total 20ml cell suspension. The cell suspension was carefully underlayed 
with 10ml Histopaque (room temperature) using a 10ml pipette and centrifuged for 30min. at 
625RCF, room temperature and without break (for gradient stability). The interphase 
containing murine MNCs was carefully collected with a 5ml pipette in a new 50ml tube and 
diluted with 10ml PBS. Cells were centrifuged for 10min at 360RCF and room temperature. 
Supernatant was removed and cell pellet was resuspended with 10ml PBS. The washing 
step was repeated and cell pellet was resuspended with 10ml PBS. Cells were counted and 
stored on ice until further use.  
3.2.2.2   Coating of Dynal-Epoxy beads with mAbs:  -CD3 and  -CD28  
For the stimulation of murine T lymphocytes, magnetic particles (M-450 Epoxy Beads) were 
coated with antibodies  -CD3 and  -CD28. Dynabeads M-450 Epoxy were resuspended by 
vortexing the container before opening. After opening the container, beads were 
resuspended by pipetting and 1ml (4 x10
8 beads) was transferred to a sterile FACS tube. The 
tube was placed in a magnetic separator. All liquid was removed and discarded with a 1000 l 
pipette, while tube was still in the magnetic separator. After removing from the separator, 1ml 
1xPBS was added to the tube and vortexed until beads were resuspended. The tube was 
again placed in the magnetic separator and the washing step was repeated. 60 g (60 l) of Methods  51
each monoclonal antibody anti-CD3 (Clone: 145-2C11) and anti-CD28 (Clone: 37.51) were 
added to resuspended 1ml bead suspension and vortexed. The lid around the top of tube 
was tightly closed and wrapped with a parafilm. The tube was placed in a 50ml Falcon tube 
and incubated on a rotator for 16 24h at 37°C. Next day, the tube with beads was removed 
from rotator and placed in a magnetic separator. All liquid was removed and discarded with a 
1000 l pipette, while tube was still in the magnetic separator. The tube was again placed in 
the magnetic separator and the washing step was repeated. 1ml PBS/0.1% MSA was added 
to the beads and the tube was placed on the rotator for washing/blocking for 5min. at room 
temperature. The tube was removed from the rotator and placed in a magnetic separator. All 
liquid was removed and discarded with a 1000 l pipette, while tube was still in the magnetic 
separator.  Washing with 1ml PBS/0.1% MSA was repeated twice.  The beads were 
resuspended in 1ml PBS/0.1% MSA and incubated on a rotator for 16 24h at 2 8°C. Next 
day, tube with beads was removed from the rotator and placed in a magnetic separator. All 
liquid was removed and discarded. The beads were resuspended with 1ml PBS/0.1% MSA 
and transferred to a new sterile FACS tube. The beads were stored (for at least 4 weeks) at 
4°C for further use.  
3.2.2.3   Stimulation of primary murine T lymphocytes 
For stimulation, murine T lymphocytes were prepared in mouse special medium. After 
washing with 2ml PBS, anti-CD3/-CD28 coupled beads were added in 3:1 beads to cell ratio 
after resuspending in 1ml of prepared cell suspension. After mixing of cell suspension and 
beads by pipetting carefully up and down, the cell/bead suspension was seeded in 6 well 
culture plates with a density of 4.2-4.9 x 10
6   cells/7ml per well. Cells were kept under 
standard cell culture conditions for 4 days. 100U/ml IL-2 was added on each day for better 
stimulation. On fourth day, cells were collected in a 50ml Falcon tube. After rigorous pipetting 
8 to 10 times up and down with a 10ml pipette, cells were debeaded by placing in a magnetic 
separator. Afterwards, the medium containing debeaded cells was transferred to a new 50ml 
Facon tube. The cells were counted and used for transduction (see sections 3.2.6/3.2.5).  
3.2.2.4   Isolation and stimulation of murine lineage negative HSCs/HPCs 
Murine lineage negative haematopoietic stem cells/haematopoietic  progenitor  cells            
(lin-HSCs/HPCs) were isolated from the bone marrow of WT mice (Ly5.1). After killing the 
mice by a nape-break, skin was disinfected with 70% EtOH. Tibia and Femur bones were 
removed from the animals (without touching the fur) and raw parts of the muscles were cut 
away. After isolation, Tibia and Femur were stored on ice in a 50ml Falcon tube containing 
isolation-buffer. For further preparation, three 10cm tissue culture dishes were prepared:       Methods  52
1. EtOH, 2. PBS, 3. Isolation-buffer. Tibia and Femur, as well as surgical instruments were 
washed with 70% EtOH for sterility and rinsed in 1xPBS. The bones were stored in the dish 
plate containing isolation-buffer. Muscle tissues and tendons were carefully removed from the 
bones to obtain a clear view on the red shimmering bone marrow. The ends of the bones 
were cut away and bone marrow was flushed with isolation-buffer filled syringe. Clumps were 
dispersed by gently resuspending the bone marrow. The cells were centrifuged for 8min. at 
320RCF and RT. Cell pellet was resuspended in 6ml isolation-buffer. Remaining clumps of 
cells and debris were removed by passing cell suspension through a 100 m mesh nylon 
strainer. Cells were counted and centrifuged for 8min. at 320RCF and RT. Supernatant was 
discarded and cells were resuspended in isolation-buffer at 1 x 10
8  cells/ml.   Isolation of 
lineage negative stem cells (lin-HSCs/HPCs) was carried out according to the manufacturers 
instructions by using  Lineage Cell Depletion Kit (Miltinye  Biotec).  5x10
5  to 1x10
6                
lin-HSCs/animal were yielded. This procedure depletes the mature haematopoietic cells, 
such as T cells,  B cells, monocytes/macrophages, granulocytes, erythrocytes, and their 
committed precursors from the bone marrow, thus leaving the lineage negative cells 
untouched that express CD117 or Sca-1 marker. The cells were cultured for 3 days in RPMI 
(Bio Whittaker, Rockville,USA), supplemented with the following cytokines: 10ng/ml murine 
IL-3, 50ng/ml murine IL-6, and 50ng/ml murine stem cell factor (SCF) (Tebu-bio, Offenbach, 
Germany). The cells were counted and used for the transduction (see sections 3.2.6/3.2.5).  
3.2.3 Production of Eco/GALV viral particles 
3.2.3.1  Transient transfection of 293T cells  
This technique is based on the unspecific uptake of plasmid-DNA-CaCl2  crystals by 293T 
cells. Since the plasmids do not integrate into the genome but exist as episomes in the cells, 
the transgene is only transiently expressed.  For this purpose, 5x10
6 293T cells were seeded 
in 8ml DMEM-standard per 10cm dish. On the next day, the medium was exchanged to 
0.25μM chloroquine in DMEM-standard (8ml). Master mixes were prepared as follows (for 
one sample):   
               7.5  μg   plasmid of interest    
     1       μg M187/ M620 (coding for Eco/GALV env, respectively)   
     12.5  μg M579 (coding for gag/pol)   
     50   μl  CaCl2 (2.5 M)  
Ad    500   μl  dH2O   Methods  53
This mix was added drop-wise to 500μl (per sample) of 2x HEPES (pH: 7.0/7.05/7.1) under 
vigorous vortexing. Mixture was incubated for 20min. at room temperature. After incubation, 
1ml from the transfection mix was pipetted to each plate under continuous shaking to yield an 
evenly distribution of transfection crystals. Cells were incubated for 8h and then the medium 
was exchanged by 6ml DMEM-standard. Next day, supernatant was harvested and new 6ml 
DMEM standard was added. Supernatant was collected 24, 36 and 48 hours after 
transfection. Collected supernatant was sterile filtrated through 0.45 μm membrane and 
stored at 4°C. All supernatants were pooled and titrated on the embryonic murine fibroblast 
SC-1 cell line (for Eco env-supernatant) or TE671 cell line (for GALV env-supernatant). 
 
3.2.3.2  Titration of the produced vector particles  
In order to determine the quantity of infectious particles in the produced gammaretroviral 
supernatant, the murine adherent cell line SC-1 and human adherent cell line TE671 were 
transduced with eco-supernatant and GALV-supernatant, respectively. For this purpose, one 
day before titration, 510
4  cells (SC-1/TE671)/well in 1ml DMEM standard medium were 
seeded in a 24-well tissue culture plate. On the next day, different quantities (between 0 and 
1000 l) of produced viral supernatant were added on to the cells and centrifuged for 1 hour 
with 2380rpm at 31°C. The total volume was kept to 1ml per well. After 2-3 days, the medium 
was removed and the cells were washed once with 1xPBS and then were trypsinized. The 
cells were resuspended with 1ml DMEM standard medium and transferred to FACS tubes. 
After washing with 2ml FACS buffer, cells were resuspended into 300 l FACS buffer and 
analyzed for eGFP fluorescence in the FACS. The titres of the viral particles were calculated 
by the following formula: 
 
Titre [infectious particles/ml] = (transduced cells [%]/100) x seeded cells x dilution factor.  
 
All the dilutions were set in duplicates and the average value was determined. The average 
titre of the produced supernatants was achieved from 1x10
5 to 4x10
6 particles per ml.  
 
3.2.4 Transduction of human T cell lines (PM-1 and Jurkat) 
In a 6-well plate, 1x10
6 cells (PM-1/Jurkat)/well/3ml (RPMI standard medium) were seeded in 
a 6-well tissue culture plate. Different quantities (between 0 and 1000 l) of produced viral 
supernatant were added on to the cells to achieve ~15% eGFP positive cells (to get single 
copy of transgene/cell) and centrifuged for 1 hour with 2380rpm at 31°C. The total volume Methods  54
was kept to 3ml per well. Afterwards, the cells were cultured for three days and analyzed by 
FACS (see 3.2.8). 
The MOI (multiplicity of infectious particle) was calculated by the following formula: 
 
MOI [infectious particles/cell] = (Titre [transfer units/ml] x volume of supernatant [ml]) / cell 
number. 
 
3.2.5 Transduction of stimulated T cells or HSCs/HPCs 
Stimulated T cells or HSCs/HPCs were transduced by culturing on virus-preloaded six-well 
plates. For this purpose, non-tissue culture treated six well plates were coated with 1ml 
retronectin solution (fibroncetin protein) over night at 4°C. The plates were blocked with 3ml 
of  2% BSA solution and subsequently washed with 3ml HBSS. 3ml virus containing 
supernatant was added to each well and six-well plates were centrifuged for 30 minutes at 
962xg at 4°C. This step was repeated twice. Virus in the supernatant adheres unspecifically 
to the retronectin-coated surface, thus allowing concentration of retroviral particles at the 
bottom of the plate. 1x10
6 stimulated lin-HSCs/HPCs in stem cell medium and 3 to 4x10
6 
stimulated T cells in mouse special medium were added per well of virus-preloaded plate and 
incubated overnight. Next day, the cells were transferred onto a second virus-preloaded plate 
(procedure repeated as above) and cultured for two days. 
 
3.2.6 Cell counting by means of  counting chamber
 
The cell number was determined by using  Neubauer cell counting chamber . 10 l  of         
well-resuspended cell suspension was mixed (diluted) with 1x trypan blue solution. Trypan 
blue is able to stain only dead cells. Thus, viable cells (unstained) were counted and dead 
cells (blue cells) were not. The mixture (approx. 10 l) was laid on to the counting chamber 
and cells were counted. 
            
                       Figure 10. Cell counting by using Neubaur counting chamber. 
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Figure 10 shows the schematic representation of counting chamber. The cell number in two 
blue big squares was determined and then divided by 2 to get the average count in one big 
square. The exact cell count was calculated by the following formula: 
Cells/ml = average count in one big square x dilution ratio (cell suspension:trypan blue) x 10
4 
 
3.2.7 Animal experimental methods 
3.2.7.1  Animal husbandry conditions  
The mice were maintained and bred according to the guidelines of FELASA (Federation of 
European Laboratory Animal Science Associations) in the animal husbandry facility of 
George-Speyer-Haus. Cages were individually ventilated (IVC). The area was entered only 
after wearing the protective clothings, face mask, gloves and overshoes. The temperature 
was constantly maintained to 22°C with the air humidity from 50 to 60%. The light rhythm 
(light/dark) followed at the interval of 12 hours. The animals were cared and checked for 
general state of health by animal care-takers, maintenance staff as well as by a veterinary 
control supervisor.  
3.2.7.2  Blood withdrawal for FACS and haemogram  
Up to 10% of the blood volume from the mice can be withdrawn usually without any 
recognizable side effects. Blood was taken from the mice either from the tail vein or by heart 
puncture (if the mouse was sacrificed).  For withdrawal from the tail vein, the mice were 
warmed up with red light lamp, then the tail vein was cut with a scalpel and the blood was 
collected with EDTA coated capillary (Microvette). 50-100 l blood was taken and used for 
FACS analysis and haemogram. ~50 l blood was used for FACS analysis (see 3.2.8). ~5μl 
blood was used for haemogram and the blood cell count was determined by using Scil Vet 
ABC (animal blood counter) in order to get a reference over the leukaemic status of the 
experimental animals. For the heart puncture, the animals were first anesthetised with 
Enfluran and then sacrificed by a neck break. The animal was fixed on a cork tray. After 
disinfecting with 70% ethanol, the chest wall was opened and blood was withdrawn with a 
1ml syringe by puncturing the heart with a scissors. Blood could be taken up to 1ml. Heparin 
was used as an anticoagulant. For the determination of haemogram, EDTA could only be 
used as an anticoagulant. Therefore, also while scarificing the animal, some blood was taken 
with EDTA-coated Microvette. 
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3.2.7.3  Sacrificing and sectioning of the animals 
Obviously sick recipients and the donor animals were anesthetized with Enfluran and 
afterwards sacrificed by a neck break. The dead animals were fixed in upside-down position 
on a cork-tray and disinfected with 70% ethanol. The skin was removed from the abdominal 
wall without damaging the internal organs. After opening the abdominal wall, all 
macroscopically visible changes of the internal organs were documented and the following 
organs were removed for further investigations: spleen, lymph nodes, thymus (if available), 
kidneys, liver, heart, lungs, brain and bones (Tibia and Femur) and/or the appropriate tumors 
(lymphomas). Before further preparation, the organs were transferred into 1xPBS and stored 
on ice.  
 
3.2.7.4  Processing of the organs for FACS and histology 
After isolation of the lymphatic organs, the single cell suspensions were made for FACS 
analysis and the part of the organs was fixed for histological analysis. From the sick animals, 
lymphatic organs (spleen, lymph nodes, thymus and bone marrow) were analyzed by FACS 
and histological examination. The individual sample was homogenized through a cell strainer 
(filter mesh) with the help of a syringe stamp in a 6-well plate and collected in a 50ml Falcon 
tube. The cell suspensions were washed once with 1xPBS and the cell number was 
determined. An appropriate cell quantity was then used for the FACS analysis and the 
remaining part of the cells was preserved at -80°C. Further, the appropriate organs were 
fixed in the 10% ZINC FORMAL FIXX solution. After 24-36 hours, the Fixx solution was 
removed and 70% ethanol was added to the stored organs. Histological sections of the fixed 
organs were made according to the regulation of the pathological data base RITA [54] and 
stained with Haematoxylin and Eosin (HE). This was done by a commercial service of the 
company MFD DIAGNOSTICS GmbH (Wendelsheim). The histological investigation was 
done in co-operation with Dr. Silvia Hartmann and Professor Dr. Martin-Leo Hansmann from 
Pathology Institute of the JWG University of Frankfurt.  
 
3.2.8 FACS analysis 
Via Flow cytometry, different physical and chemical characteristics of individual cells or 
particles are measured at the same time. The cells are arranged one behind the other in a 
flow direction and examined separately by means of a laser beam. Due to its scattered light 
characteristics, cell size (forward scatter, FSC) and granularity (sideward scatter, SSC) can 
be determined for several thousand individual cells. After staining with a fluorochrome 
conjugated-antibody or by the expression of fluorescent protein (e.g. green fluorescent Methods  57
protein, GFP), the cells are sensed by the laser beam. Surface proteins can be recognized 
with a primary fluorochrome-coupled antibody. For FACS analysis, CellQuest pro (BD) was 
used in the available work. For this purpose, ~5 x 10
5 cells were transferred into 5ml round 
bottom FACS tubes. The cells were washed twice with 2ml FACS-buffer by centrifugation. 
Supernatant was discarded and cells were resuspended in 300μl FACS-buffer. For blood or 
homogenized organ cell suspensions,  erythrocytes were lysed by using cal-lyse solution. 
After staining with antibodies, the cells (WBCs) were washed twice with PBS and 
resuspended in 300μl FACS-buffer. Afterwards, the cells were analyzed by FACS.  Results  58
4.  Results
 
It is not clear yet whether the mature T cell leukaemias/lymphomas originate from the 
haematopoietic stem cells/haematopoietic progenitor cells (HSC/HPC), later T cell 
progenitors, or the mature T cells themselves. As already described (see 1.1) for myeloid 
leukaemias, there is a growing evidence that they originate from HSCs/HPCs or early 
myeloid progenitors. For B cells it was recently shown that mature B lymphocytes can still be 
transformed; but for mature T cells, several observations indicate that these cells are less 
susceptible to transformation than HSCs/HPCs. To further investigate the transformation 
susceptibility of mature T cells in comparison with HSCs/HPCs, we introduced 
gammaretroviral vectors encoding the potent  T cell oncogenes  NPM-ALK (a fusion 
oncogene) and Tax (a viral oncogene), and the T cell potential oncogene p21SNFT into both 
cell types and then transplanted them into mouse models.   
4.1   Cloning of gammaretroviral vectors 
For the transduction of HSCs/HPCs and mature T cells, gammaretroviral vectors were cloned 
that coded for the potent T cell oncogenes NPM-ALK and Tax, and the T cell potential 
oncogene p21SNFT. Figure 9 shows a schematic representation of the cloned vectors. 
 
Figure 11. Structure of the gammaretroviral vectors. For cloning, MP91-eGFP gammaretroviral 
vector (control) was used, which encodes mcs, an IRES-element and the expanded green fluorescent 
protein (eGFP). To enhance the expression of the respective transgene, a wPRE element (Woodchuck 
hepatitis virus post transcriptional regulatory element) was used. 
 
The gammaretroviral vector MP91-eGFP was used as the basic construct for the cloning. 
This vector encodes for a mcs (multiple cloning site), an IRES- element (internal ribosome 
entry site) and the gene for the expanded green fluorescent protein (eGFP), which serves as    Results  59
a marker and a control gene. The  cDNAs of NPM-ALK,  Tax and p21SNFT were cloned 
individually into the MP91-eGFP vector in the available work. 
4.1.1 Cloning of NPM-ALK and p21SNFT 
The plasmid B-NPM-ALK (containing NPM-ALK insert) and the  gammaretroviral vector 
MP91-eGFP were both digested with the restriction enzymes AgeI and NotI (for maps see 
appendix). The digestion cuts the NPM-ALK insert out of the B-NPM-ALK plasmid and the 
MP91-eGFP retroviral vector in the mcs to produce corresponding sticky ends. The isolated 
fragments were then ligated to get the resultant vector MP91-NPM-ALK (see figure 12). 
p21SNFT was also cloned with the same strategy, resulting in the vector MP91-p21SNFT 
(see figure 12).  
 
(1) Digestion of plasmids containing NPM-ALK and p21SNFT with AgeI and NotI: 
 
 
 
 
 
(2) Digestion of MP91-eGFP gammaretroviral vector at mcs with AgeI and NotI: 
 
 
 
         
 
(3) Resultant MP91-NPM-ALK vector after ligation of the NPM-ALK insert (from step 1) and the 
MP91-eGFP gammaretroviral vector (from step 2):   
               
 
(4) Resultant MP91-p21SNFT vector after ligation of the p21SNFT insert (from step1) and the 
MP91-eGFP gammaretroviral vector (from step 2):   
 
 
 
Figure 12. Cloning strategy for NPM-ALK and p21SNFT. (1) Digestion of B-NPM-ALK plasmid 
(containing  NPM-ALK insert) and B-p21SNFT plasmid (containing p21SNFT insert) with restriction 
enzymes AgeI and NotI. (2) Digestion of gammaretroviral vector MP91-eGFP with restriction enzymes 
AgeI and NotI. (3) Resultant vector MP91-NPM-ALK after ligation of NPM-ALK insert and digested 
MP91-eGFP retroviral vector. (4) Resultant vector MP91-p21SNFT after ligation of p21SNFT insert 
and digested MP91-eGFP retroviral vector. 
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4.1.2 Cloning of Tax M 
For Tax, its murine codon optimized form  Tax M was  used  for expression in murine cells. As 
the restriction sites in the plasmid  B-Tax M
 
and gammaretroviral vector MP91-eGFP did not 
match for cloning, the gene for Tax M was first cloned into the Bluescript plasmid M23 (which 
had resembling restriction sites), which was then  transferred into gammaretroviral vector 
MP91-eGFP (for maps see appendix). The whole cloning strategy for Tax M is depicted in 
figure 13 A and B.  
 
(1) Digestion of the Bluescript M23 with XmaI, and the plasmid B-Tax M (containing Tax M insert) 
with NotI    
 
 
 
 
 
 
(2) Linearized Bluescript M23 and Tax M plasmids with sicky ends:  
 
 
 
       
 
(3) Treatment of the above products (step 2) with Klenow to generate blunt ends: 
 
 
 
         
 
(4) Digestion of linearized blunt ended M23 and Tax M plasmids (step 3) with BamHI: 
 
                     
 
(5) Intermediate vector  M23-Tax M  after ligation of the above products (step 4): 
 
 
 
 
                 
Figure 13 A. Cloning of Tax M into Bluescript M23. (1) Digestion of the Bluescript M23 with XmaI, 
and the plasmid B-Tax M (containing Tax M insert) with NotI to linearize (open) both the plasmids. (2) 
Linearized Bluescript M23 and B-Tax M plasmids with sicky ends, resulting from the step 1 digestion. 
(3) Treatment of both sticky ended M23 and Tax M plasmids with Klenow to generate blunt ends. (4) 
Digestion of both linearized blunt ended M23 and Tax M plasmids with BamHI to produce the 
corresponding sites. (5) Ligation of step 4 products, resulting in the intermediate vector M23-Tax M . 
M23  Tax M 
NotI NotI XmaI XmaI
M23  Tax M 
M23  Tax M 
M23  Tax M 
M23  Tax M 
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The plasmid B-Tax M (containing Tax M) was digested with NotI, and the Bluescript plasmid 
M23  with XmaI to open (linearize) both the plasmids. As this digestion resulted in 
mismatched sticky ends due to the use of different sticky cutters (restriction enzymes), both 
vectors (linearized B-Tax M and M23) were treated with Klenow to generate blunt ends. 
Afterwards, both vectors were digested with BamHI. The digestion cuts the Tax M insert out 
of linearized B-Tax M plasmid and the M23 linearized vector to produce corresponding sticky 
ends. The fragments were ligated. Thus, an intermediate vector  M23-Tax M was  cloned 
(see figure 13 A), which carried matching restriction sites for cloning into the gammaretroviral 
vector. The intermediate cloned plasmid  M23-Tax M and  the  gammaretroviral  vector  MP91-
eGFP both were digested with EcoRI and NotI enzymes. The digestion cuts the Tax M insert 
out of  M23-Tax M and  the  MP91-eGFP gammaretroviral vector in the mcs. The isolated 
fragments were then ligated to get the resultant vector MP91-Tax M (see figure 13 B). 
 
(1) Digestion of intermediate vector M23-Tax M with EcoRI and NotI: 
 
 
 
 
 
      
 
(2) Digestion of gammaretroviral vector MP91-eGFP with EcoRI and NotI: 
               
 
(3) Resultant MP91-Tax M vector after ligation of the Tax M insert (from step 1) and the 
MP91-eGFP retroviral vector (from step 2): 
 
 
 
       
 
Figure 13 B. Cloning of Tax M (from intermediate vector M23-Tax M) into gammaretroviral 
vector M91-eGFP. (1) Digestion of intermediate vector M23-Tax M with EcoRI and NotI. (2) Digestion 
of gammaretroviral vector MP91-eGFP with EcoRI and NotI. (3) Resultant MP91-Tax M vector after 
ligation of the Tax M insert (from step 1) and the MP91-eGFP retroviral vector (from step 2). 
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Thus, the isolated fragments of all the three genes (NPM-ALK, p21SNFT and Tax M) were 
individually inserted into MP91-eGFP vector directly before the IRES element in order to 
enable bicistronic expression of oncogene and marker gene (eGFP). All cloned constructs 
were verified by sequencing. Possible mutations were excluded.  
 
4.2   Packaging of cloned constructs 
Packaging was performed in 293T cells as described in section 3.2.3.1. For this purpose, the 
envelopes derived from the Gibbon ape leukaemia virus (GALV) and the ecotropic murine 
leukaemia virus (Eco) were used to produce supernatants for the transduction of human T 
cell lines and murine cells, respectively. One day after packaging, green cells under the 
fluorescent microscope confirmed successful transfection (Figure 14).  
    
 
 
 
                  
 
 
Figure 14. Green cells observed in the fluorescent microscope 24 hours after transfection. 
 
The  GALV supernatant  was  used for in vitro experiments with human T cell lines (PM-1 and 
Jurkat), while the  Eco supernatant  was  used  for  in vivo experiments with murine models. All 
supernatants were pooled at 4
0C for at least 10 days until further use. 
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4.3   Western blot analysis for protein expression  
Western blotting was performed to check for protein expression of cloned constructs. As Tax 
is a viral oncoprotein, transfected human  293T cells  were  used  for its expression. But, ALK 
and p21SNFT are human genes and they could be expressed naturally in human cells, as 
antibodies used for the detection of NPM-ALK expression bind to its ALK portion. Therefore, 
to exclude a positive signal from the corresponding endogenous proteins in human cells, 
different species cells (murine cells  SC-1 ) were transduced with both of these constructs 
individually and analyzed for respective protein expression. For this purpose, Tax transfected 
293T cells (see section  3.2.3.1) and NPM-ALK  or  p21SNFT transduced SC-1 cells (see 
section 3.2.3.2) were used. Two days after transfection/transduction, cells were trypsinized 
and washed with PBS to be used for Western blotting. Western blotting was performed as 
described in the section 3.1.12.  Expression was confirmed for all three construts by 
comparing their sizes with the standard marker  kDa . As negative controls, untransfected 
293T cells for Tax and untransduced SC-1 cells for NPM-ALK and p21SNFT were used. 
Thus, the expression of all these oncogenes on protein level was confirmed (see figure 15).  
 
 
 
 
 
                    
Figure 15. Protein expression of transfected/transduced oncogenes. Tax expression in 293T cells 
(upper band, 40 kDa). NPM-ALK expression in SC-1 cells (middle band, 80 kDa). p21SNFT 
expression in SC-1 cells (lower band, 14.5 kDa). As negative controls, corresponding untransfected/ 
untransduced cells (wild type) were used (right empty portion of the corresponding gel). WT: wild type.  
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4.4   In vitro Experiments 
4.4.1 Effects of p21SNFT, Tax M and NPM-ALK on human T cell lines 
To observe the in vitro effects on cell growth of T cells, two T cell lines (Jurkat and PM-1) 
were transduced with p21SNFT,  Tax M and NPM-ALK  supernatants (GALV env) and 
followedup for eGFP marking and cell growth. eGFP transduced cells were used as controls. 
Both cell lines  showed comparative transduction efficacies for transferred genes                
(see figure 16). 
Different MOIs of vector supernatants were used to achieve ~15% eGFP positive cells to 
confer single copy of gene in the transduced cells (see section 3.2.4). Gene marking and the 
growth (counting) were monitored every second day. For  NPM-ALK and Tax  M, eGFP 
marking declined from ~15% to <1% in both T cell lines over 12 to 14 days after transduction, 
while the eGFP marking for the control cells remained stable (Figure 17 A/B).  For both, 
NPM-ALK and Tax M, cells also grew slower as compared to the control eGFP transduced 
cells (Figures 17 E/F). 
 
 
 
For p21SNFT, the eGFP marking declined very slowly from 13% to 5% in both T cell lines 
over 42 days after transduction, while the eGFP marking of the control cells remained stable 
(Figures 17 A/B). The cell counts for both, p21SNFT and the control eGFP were comparable 
in both T cell lines and no big difference could be observed (Figures 17 C/D). 
Thus, no growth or proliferation promoting effect of all these genes could be observed. As for 
NPM-ALK and Tax M, eGFP marking declined from ~15% to <1%, LM-PCR was performed 
Figure 16. (A) Transduction efficacies of constructs in PM-1 cell line.
 
eGFP control: 87%; 
p21SNFT: 85%; Tax M: 45%; NPM-ALK: 60%. (B) Transduction efficacies of constructs in Jurkat 
cell line. eGFP control: 75%; p21SNFT: 80%; Tax M: 50%; NPM-ALK: 55%. Black bars: eGFP 
control; dark grey bars: p21SNFT; light grey bars: Tax M; white bars: NPM-ALK.  Results  65
to  further  investigate  if  the  transgene  was  still  present  in  the  transduced  cells,                   
(see section 4.4.2). 
 
 
Figure 17. Effects of p21SNFT, Tax M and NPM-ALK on human T cell lines.  
eGFP marking for all three oncogenes declined over time, while the control cells stably expressed 
eGFP in both T cell lines, (A) PM-1, (B) Jurkat. Cell growth for p21SNFT was comparable to eGFP 
control in both T cell lines, (C) PM-1, (D) Jurkat. Cell growth for NPM-ALK and Tax M was less 
exponential in comparison to eGFP control in both T cell lines, (E) PM-1, (F) Jurkat. Black line: eGFP 
control; grey line:  p21SNFT; red line: Tax M; blue line: NPM-ALK. Note: NPM-ALK and Tax M 
transduced cells were observed for 14 days due to loss of eGFP marking.  
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4.4.2 LM-PCR for NPM-ALK and Tax M transduced T cell line 
NPM-ALK and Tax M transduced both T cell lines (PM-1 and Jurkat) showed decline in eGFP 
marking from ~15% to <1%. LM-PCR was performed to check if the transgene was still 
present in the transduced cells. For this purpose, DNA was isolated from NPM-ALK and     
Tax M transduced Jurkat cells before and after the decline of eGFP expression (~15% and 
<1%). LM-PCR was performed as described in the section 3.1.11. Figure 18 shows the result 
of the LM-PCR, in which both (NPM-ALK and Tax M) transduced cells with ~15% eGFP 
expression  show oligoclonal integration pattern ( 8  bands),  while  cells  with  <1%  eGFP 
expression show only one band which refers to the internal control (figure 18, band depicted 
in blue box). An explanation for that fact is described in the discussion part (see 5.1).     
 
 
 
Figure 18. LM-PCR of Tax M and NPM-ALK in Jurkat T cell line. For both (Tax M and NPM-ALK), 
oligoclonal integration pattern (  8 bands) can be seen in the cells expessing 15% eGFP, while no 
integration in the cells expressing <1% eGFP could be observed except for the internal control band 
(blue box). C: eGFP control cells expressing ~15% eGFP. 
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4.5   In vivo experiments 
4.5.1 Mouse models: Transplantation protocol and follow up  
After transduction (see section 3.2.5), 1-2x10
7 polyclonal T cells (from C57BL/6J.Ly5.1 mice) 
or  monoclonal T cells (from C57BL/6Tg.Ly5.2 mice) and 3-5x10
5  HSCs/HPCs (from 
C57BL/6J.Ly5.1 mice) were transplanted into RAG-1 deficient recipient mice (C57BL/ 
6J.Ly5.2 background). The cells were injected into the tail vein of the recipients. One day 
before transplantation with murine stem cells, recipient mice were sublethally irradiated with 
5Gy. After 16-24 weeks, animals that received T cell transplants developed a massive colitis 
and were sacrificed. T cells were isolated from spleen and lymph nodes and serially 
transplanted into the secondary recipients. The basic transplantion protocol is shown in figure 
19.   
 
Figure 19. Transplantion principle and serial transplantation. C57BL/6 (Ly5.1 or OT-I) WT mice 
were used as donors for murine T cells (TC) and lineage negative HSCs/HPCs. Isolated lineage 
negative HSCs/HPCs were stimulated for 3 days and mature T cells for 4 days. Subsequently after 
retroviral transduction, the cells were transplanted in to Rag-1 deficient mice. After 16-24 weeks, 
polyclonal T cell transplanted animals developed massive colitis and were sacrificed. After isolating T 
cells from spleen and lymph nodes, those cells were serially transplanted into secondary recipients 
(always one donor for one recipient).   
4.5.2 Comparable levels of retroviral transduction and expression of 
the oncogenes in HSCs/HPCs, mature T cells and their respective 
progeny 
After isolation, mature T cells were stimulated with anti-CD3/-CD28 coupled paramagnetic 
beads for 4 days, and HSCs/HPCs were stimulated with mIL-3, mIL-6 and mSCF for 3 days 
(see section 3.2.2).  After two rounds of transductions with ecotropic vector supernatants, the Results  68
transgene expression was measured by FACS. For mature T cells, 20 to 67% and for 
HSCs/HPCs, 25 to 48% transduction efficacies were achieved (see figure 20).  
 
Figure 20. Transduction efficacies of oncogenes in stimulated murine HSCs/HPCs and mature 
T cells. The overall transduction efficacies achieved for each construct were: p21SNFT: 47 to 65%; 
NPM-ALK: 9 to 25%; Tax M: 21 to 27%. Black bars: haematopoietic stem cells; white bars: polyclonal 
T cells; gray bars monoclonal T cells (OT-1).  
After transduction, the cells were transplanted into Rag-1 deficient mice. Table 24 shows the 
number of transplanted mice with each cell type (transduced with each construct).    
     Table 24. Number of transplanted mice with each cell type/construct. 
Construct  HSCs transplanted mice Polyclonal T cell 
transplanted mice 
Monoclonal T cell 
transplanted mice 
p21SNFT  5 6  7 
NPM-ALK  3 5  5 
Tax M  10 6  12 
 
 
The animals were analyzed for donor cell engraftment and transgene (eGFP) expression 6 
weeks after transplantation by collecting blood from the tail vein. Expression of donor marker 
(CD45.1), T cell marker (CD3) and the transgene (eGFP) was determined by FACS analysis. 
This procedure was performed every 6 to 8 weeks to check for the transgene expression and 
any indication for the development of leukaemia/lymphoma.  Figure  21 shows eGFP 
expression in the T cell compartment of all transplanted groups 6 weeks after transplantation. 
The overall eGFP expression in T cell compartment was 20 to 73% for all the p21SNFT Results  69
transplanted groups (haematopoietic stem cell, polyclonal T cell and monoclonal T cell). For 
NPM-ALK animals, eGFP expression could not be observed 6 weeks after transplantation. 
Subsequently, the NPM-ALK_OT-I transplanted group expressed eGFP 7 to 9 weeks after 
transplantation.  From  Tax M group, the eGFP expression could not be observed for the 
whole observation period of ~8 months, although enfragted cells were positive for the donor 
marker (CD45.1) and T cell marker  (CD3). MP91-eGFP  control vector transplanted mice 
were already used and showed a stable expression of eGFP [55].       
             
Figure 21. eGFP expression in T cell compartment of all transplanted groups 6 weeks after 
transplantation. For p21SNFT: stem cell transplanted group: 20 to 45% (black bar), polyclonal T cell 
transplanted group 35 to 73% (white bar), monoclonal T cell (OT-1) transplanted group: 39 to 59% 
(gray bar). For NPM-ALK and Tax M transplanted groups, no eGFP marking could be observed. S: 
stem cell; P: polyclonal T cell; M: monoclonal T cell. 
 
4.5.3 Oncogenes transform primary murine mature T cells and 
HSCs/HPCs after retroviral transduction 
After transplantation of oncogene-transduced HSCs/HPCs and mature T cells, some of the 
animals from the NPM-ALK and p21SNFT groups developed haematological malignancies 
with characteristic latencies. The tumors showed massive enlargements of spleen 
(splenomegaly) and, mesenteric and paraspinal lymph nodes (lymphoma). In some cases, 
white blood cell counts (WBC) were elevated (upto 74 x 10
3/ l, control 15 x 10
3/ l)  and 
showed leukaemic characteristics. The details of these tumors are described as below: 
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4.5.3.1  NPM-ALK induced tumors 
4.5.3.1.1 Tumor development  after transplation of NPM-ALK transduced OT-1 
cells 
All  5 mice transplanted with NPM-ALK transduced monoclonal mature T cells (OT-I) 
developed leukaemia/lymphoma with massive enlargements of liver (hepatomegaly), spleen 
(splenomegaly) and mesenteric lymph nodes 45 to 64 days after transplantation. Figure 22A 
shows the survival curve of this group (red line). Only 3 out of 5 mice could be analyzed 
because, unfortunately 2 of them died overnight and were autolytic. Nevertheless, autopsy of 
these two mice showed massive enlargements of spleen and lymph nodes. In FACS 
analysis, the tumors from analyzed mice were positive for 6 to 45% eGFP marking (figure 
22B), but very low percentages of different cell populations like, TCR /
 
(common TCR), 
V 2/V 5 (OT-I specific TCR), CD8, CD4, CD19, NK1 (natural killer), and a high percentage 
of CD11b (myeloid marker) population in the eGFP negative population. The eGFP 
expressing cells did not express any lineage marker.  
 
 
Figure 22. (A) Survival curve of NPM-ALK transplanted mice. All 5 mice transplanted with 
transduced monoclonal T cells (OT-1) developed leukaemia/lymphoma (red line), while only 2 out of 5 
mice transplanted with transduced polyclonal T cells (black dotted line) and 1 out  of 3 mice 
transplanted with transduced haematopoietic stem cells (black line) developed leukaemia/lymphoma. 
(B)  eGFP expressions in NPM-ALK_OT-I  tumors. Mouse # 2 (A2): 27%, Mouse # 3 (A3): 6%, 
Mouse # 4 (A4): 45%.  
To  exclude  contaminating (non malignant) cells from the tumors, the tumor cells 
(supplemented with IL-2) were kept in culture for two weeks and again analyzed by the 
FACS. CD11b marker as well as the other markers remained undetected. Furthermore, the 
tumor cells from three mice of this group were serially transplanted into Rag-1 deficient mice. 
After 3 to 4 weeks of transplantation, two of them developed the same tumors with the same 
phenotype corresponding to the donor mice tumors 3 to 4 weeks after serial transplantation. Results  71
Thus, again, the tumors could not be analyzed to a clear haematopoietic lineage by FACS 
analysis. The FCAS findings of these tumors are summed up in Table 25.   
     Table 25. FACS findings of tumors from NPM-ALK_OT-I cell transplanted mice.   
Muose   eGFP  TCR  
/
 
V 2   V 5  CD8  CD4   CD19  CD11b   NK1  WBC > 
15000/ l 
2  27 2 7 0  0 0  1  30 1  No 
3 6  2  11 9 11 2  <1  76 6  Yes 
3 (sr.tx) 2  <1  <1 0 0  0  0  76 1  n.m 
4  45 1 0 0  0 0  2  25  <1  n.m 
4 (sr.tx)  17  <1 0  0 0  0  0  54 0  Yes 
 
The tumors were positive for 6 to 45% eGFP marking (figure 22B), but very low percentages of different cell 
populations like, TCR / (common  TCR),  V 2/V 5 (OT-I specific TCR), CD8, CD4, CD19, NK1 (natural killer), 
and a high percentage of CD11b (myeloid marker) population in the eGFP negative compartment. The eGFP 
expressing cells did not express any lineage marker. All the values are in percentages (%). tx: transplantation; 
sr.tx: serially transplanted; n.m: not measured.   
Histopathological analysis for these tumors revealed  anaplastic lymphoma
 
phenotype 
(Figure 23 A/B, data not shown   M. L. Hansmann).  
4.5.3.1.2  Tumor development after transplantation of NPM-ALK transduced 
polyclonal T cells  
Two out of five mice transplanted with NPM-ALK transduced polyclonal T cells developed 
leukaemia/lymphoma with massive enlargements of liver (hepatomegaly) and spleen 
(splenomegaly) 153 to 250 days after transplantation (figure 22 A). In FACS analysis, no 
phenotype of the tumors could be identified.   
Table 26. FACS findings of tumors from NPM-ALK_polyclonal T cell transplanted mice. 
Mouse   eGFP  CD3  CD45.1  CD8  CD4  CD19  CD11b  NK1  WBC 
>15000/ l
3 2  17  18  10 8  1  10 1  No 
5 0  0  12 0  0  0  0  0  No 
 
Tumors showed different cell populations which were positive for donor cell marker (CD45.1) and either T 
cell (CD3), B cell (CD19), natural killer (NK), or myeloid cell (CD11b) marker but did not show any eGFP 
marking except one tumor (mouse 3) which showed 2% eGFP as well. The eGFP expressing cells did not 
show any linage marker.   
Although the tumors showed different cell populations which were positive for donor cell 
(CD45.1) and either T cell, B cell or myeloid cell marker, but they did not express any eGFP Results  72
marking except for one tumor which expressed 2% eGFP as well. These 2% eGFP positive 
cells did not show any lineage specific marker.  Table 26 shows the FACS findings of these 
tumors. 
Histopathological analysis for these tumors revealed anaplastic lymphoma phenotype (Figure 
23 C/D, data not shown   M. L. Hansmann).    
                                                    
Figure 23. (A) Histopathology of NPM-ALK induced leukaemia/lymphoma.  
(A) Autopsy of animal 3_NPM-ALK_OT-I. Gorss enlargement of mesenteric lymph nodes and spleen 
(splenomegaly) can be seen. (B) Mesenteric lymph node of animal 3_ NPM-ALK_OT-I.  Tumor section 
showing undifferentiated lymphocytes (anaplasia), infiltrated with granulocytes. (C) Autopsy of animal 
3_NPM-ALK_Polyclonal  T cell. Gorss enlargements of liver (hepatomegaly) and spleen 
(splenomegaly)  with tumor masses (white patches) can be seen. (D) Spleen of animal 3_ NPM-
ALK_Polyclonal T cell. Undifferentiated lymphocytic infiltration (anaplasia) can be seen. (E) Autopsy of 
animal 1_NPM-ALK_HSC.  A grossly enlarged haemorrhagic mesenteric mass infiltrated into 
intestines. (F) Mesenteric tumor mass of animal 1_NPM-ALK_HSC.  Tumor section showing 
undifferentiated lymphocytic infiltration (anaplastic).  
4.5.3.1.3  Tumor development after transplation of NPM-ALK transduced 
HSCs/HPCs  
One out of the three mice transplanted with NPM-ALK transduced HSCs/HPCs developed a 
massively enlarged mesenteric tumor mass (lymphoma) 158 days after transplantation. In the 
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FACS analysis, the tumor showed different cell populations which were positive for donor cell 
(CD45.1) and either T cell, B cell or myeloid cell marker, but did not express any eGFP 
marking (see table 27).   
  Table 27. FACS findings of the tumor after transplation of NPM-ALK transduced HSCs/HPCs.  
Mouse  eGFP  CD3   CD45.1  CD8   CD4   CD19  CD11b  NK1  WBC >15000/ l 
1 0  33  60  18  20  14 4  2 n.m 
 
The tumor showed different cell populations which were positive for donor cell marker (CD45.1) and either T cell 
(CD3), B cell (CD19), natural killer (NK), or myeloid cell (CD11b) marker but did not show any eGFP marking. 
n.m: not measured.   
Histopathological analysis for the tumor revealed anaplastic lymphoma type (Figure 23 E/F, 
data not shown   M. L. Hansmann).   
4.5.3.2  P21SNFT induced tumors 
From  p21SNFT group, only  2 out of 7 mice transplanted with p21SNFT  transduced 
monoclonal mature T cells (OT-I) developed leukaemia/lymphoma (see section 4.5.3.2.1). 
None of the mice transplanted with p21SNFT transduced HSCs/HPCs or polyclonal T cells 
developed leukaemia/lymphoma upto 240 days post-transplantation (figure 24 A).   
 
Figure 24 A. Survival curve of p21SNFT transplanted mice. Only 2 out of 7 mice transplanted with 
p21SNFT transduced monoclonal T cells (OT-1) developed leukaemia/lymphoma (red line). None of 
the mice transplanted with p21SNFT transduced polyclonal T cells (black dotted line) and 
haematopoietic stem cells (black line) developed leukaemia/lymphoma up to followup of 240 days. B. 
FACS analysis of p21SNFT_OT1 transplanted mice tumors.  Enlarged spleens/lymph nodes 
(lymphomas) were analyzed by FACS. Almost all cells (98%) were double positive for eGFP and CD19 
in both mice tumors.       Results  74
4.5.3.2.1  Tumor development after transplantation of p21SNFT transduced OT-
I cells  
2 out of 7 mice transplanted with p21SNFT transduced monoclonal mature T cells (OT-I) 
developed  leukaemia/lymphoma 144 to 200 days after transplantation (figure  24 A).  The 
tumors showed massive enlargements of mesenteric,  paraspinal and superficial inguinal 
lymph nodes (lymphomas) infiltrating the surrounding organs. In FACS analysis, the tumors 
showed high eGFP and CD19 markings (figure 24 B).  
Histopathological analysis for these tumors revealed  anaplastic lymphoma
 
type (Figure 25, 
data not shown   M. L. Hansmann).   
           
                             
 
Figure 25.  Histopathology of p21SNFT induced leukaemia/lymphoma.  (A) Autopsy of animal 
3_21SNFT_OT-I. Gorssly enlarged mesenteric lymph node mass, and liver with a tumor mass (round 
white). (B) Mesenteric lymph node (lymphoma) of animal 3_ p21SNFT_OT-I. Tumor section showing 
undifferentiated lymphocytes (anaplasia).  
4.5.4 LM-PCR analysis for the Tax transplanted group  
As already mentioned (see section 4.5.2), form Tax transplanted group, none of the mice 
expressed any eGFP marking, although they expressed the donor cell marker CD45.1/OT-I 
and  T cell (CD3) marker.  Furthermore, the recipients did not show any signs for 
leukaemia/lymphoma. To further investigate if the gene modified cells were present in the 
recipients, LM-PCR was performed by isolating DNA from one mouse of each Tax-
transplanted group (HSC, polyclonal T cell and OT-I  T cell).  LM-PCR was performed as 
described in the section 3.1.11. For this purpose, animals were sacrificed and DNA was 
isolated from the splenocytes. LM-PCR revealed oligoclonal pattern ( 10 bands) of the 
transduced cells in all three groups of animals (figure  26),  which indicates that Tax 
transduced cells were still repopulating the recipients, but did not express the transgene 
anymore. 
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Figure 26. LM-PCR of Tax transplanted group. Oligoclonal pattern ( 10 bands) of the transduced 
cells can be seen in all three groups. HSC: Haematopoietic stem cell. PolyT: Polyclonal T cell. OT-I: 
Monoclonal T cell (OT-I).  C: Negative control.   
4.5.5 Analyses of clonal pattern and gammaretroviral integration 
sites for the tumors via LM-PCR 
With the help of LM-PCR, clonal patterns and gammaretroviral integration sites for all the 
NPM-ALK and p21SNFT induced tumors were analyzed, which are as follows:  
4.5.5.1  Clonal pattern of NPM-ALK induced tumors 
From  the  NPM-ALK transplanted group, all induced tumors showed oligo- to monoclonal 
pattern. They are individually described as below:  
4.5.5.1.1 Clonal pattern of NPM-ALK_OT-1 tumors 
Three tumors were analyzed from this group. Mouse 2 and 3 showed oligoclonal, while 
mouse 4 showed monoclonal pattern (figure 27). The cells from all these tumors were serially 
transplanted into secondary recipients as well as cultured in the cell culture. Two of these 
mice (mouse 3 and 4) developed leukaemia/lymphoma 3 to 4 weeks after serial 
transplantation. Also in the cell culture, tumor cells from these mice (3 and 4) survived. In LM-
PCR analysis, mouse 3 tumor cells (both, serially transplanted mouse-tumor and cultured 
cells) showed monoclonal pattern of the same fragment size (Figure 27, lane 3, 4, 5), while 
for serially transplanted mouse 4 tumor, no DNA fragment could be observed but the cultured 
cells from mouse  4 tumor showed the same monoclonal integration pattern of the same 
fragment size (Figure 27, lane 6,7,8).  Results  76
 
 
 
 
 
 
 
 
 
 
 
Figure 27. LM-PCR of NPM-ALK_OT-1 tumors. Mono- to oligoclonal pattern in all tumors (red box), 
Internal control (blue box). A2 shows 2 fragments. A3 shows 2 fragments, but after serial 
transplantation (A3 sr.tx) and culturing (A3 culture), the cells show single fragment. A4 shows single 
fragment, but after serial transplantation (A4 sr.tx), required fragment could not be detected, while the 
cultured cells (A4 culture) show the single fragment of same size. A: animal number, sr.tx: serially 
transplanted.   
4.5.5.1.2 Clonal pattern of NPM-ALK_polyclonal T cell tumors 
From this group, 2 out of 5 mice (mouse 3 and 5) developed tumors. In LM-PCR analysis, 
mouse 3  showed monoclonal, while mouse 5 showed oligoclonal integration pattern (Figure 
28, lane 2 and 3.)  
4.5.5.1.3  Clonal pattern of NPM-ALK_HSC tumors 
From this group, only 1 out of 3 mice developed tumor. In LM-PCR analysis, the tumor 
showed oligoclonal pattern (Figure 28, lane 1).  
                          
                                 
 
Figure 28. LM-PCR of NPM-ALK (HSC/Polyclonal  T cell group) tumors. Mono- to oligoclonal 
pattern in all tumors (red box), Internal control (blue box). Tumor from NPM-ALK_HSC transplanted 
mouse 1 (lane 1) shows oligoclonal pattern. Tumors from NPM-ALK_polyclonal T cell transplanted 
mouse 5 (lane 2) shows monoclonal, while mouse 3 (lane 3) shows oligoclonal pattern. A: animal 
number; HSC: haematopoietic stem cell; PolyT: Polyclonal T cell.  Results  77
4.5.5.2  Clonal pattern of p21SNFT induced tumors 
From this group, only 2 mice (mouse 3 and 5)  transplanted with p21SNFT  transduced 
monoclonal T cells (OT-I) developed leukaemia/lymphoma. Only one of these tumors (mouse 
3) was analyzed in LM-PCR, which showed monoclonal pattern (Figure 29).  
                                                    
 
Figure 29. LM-PCR of p21SNFT_OT-I tumor. Tumor from p21SNFT_OT-1 transplanted mouse 3 
shows monoclonal pattern (red box). Internal control (blue box). A: animal number.   
4.5.5.3  Gammaretroviral integration site analysis for NPM-ALK and p21SNFT 
induced tumors 
Gammaretroviral integration sites were analyzed via LM-PCR for all induced tumors to see 
the  transgene-surrounding  oncogenes that might have contributed  in the development of 
tumor. For NPM-ALK and p21SNFT oncogene vectors, genomic regions flanking the 
retroviral integrations in tumor cells were obtained by using LM-PCR. They were sequenced 
and aligned to the mouse genome. Hit loci were examined for the nearest genes to the vector 
integrations as well as the genes within a 200kb upstream and downstream window. Genes 
in this window were analyzed for appearance in the RTCGD (retroviral tagged cancer gene 
database)  [56]  and  NCBI database, which describe the preferential integration of 
gammaretroviruses and a list of mouse genome, respectively.  When comparing genes within 
+/-200kb window of the integrations with RTCGD database, from NPM-ALK_polyclonal T cell 
A3 tumor, only 1 out of 29 integration site flanking genes (~3%) was found in the RTCGD, 
which was Irak2, while from p21SNFT_OT-I A3 tumor, 2 out of 9 integration site flanking 
genes  (22%)  were found in the RTCGD,  which were Hck and Plagl2. In  general, when 
compared to the mouse genome, there were some interesting genes near the transgene 
integrations  which are known to play an important role in cell  cycle, cell survival and 
proliferation, and apoptosis. Some of those genes are as follows: 
 
In the NPM-ALK_OT-I group: Map4k, Bfkbib, Jak3, Pak4, IL-17, Eif3s12. Results  78
 
In the NPM-ALK_polyclonal T cell group: Irak2, IL-6, IL-17rc, IL-17rE, Cidec. 
 
In the NPM-ALK_stem cell group: Trafs, Macc1. 
 
In the p21SNFT group: Hck, Plagl2. 
A detailed list of all integration sites and their surrounding genes in NPM-ALK and p21SNFT 
induced tumors can be found in the supplementary data (see appendix, 7.3).  Discussion  79
5.  Discussion
 
To investigate at which stage of differentiation mature T cell leukaemia/lymphoma is initiated, 
we introduced gammaretroviral vectors encoding the potent T cell oncogenes NPM-ALK and 
Tax, and the T cell potential oncogene p21SNFT into different cell types, i.e, haematopoietic 
stem cells, polyclonal T cells and monoclonal T cells, and then transplanted into Rag-1 
deficient mice. First, we analyzed the in vitro effects of these genes on two different human T 
cell lines (Jurkat and PM-1). No growth or proliferation promoting effect for the analyzed 
genes was observed. In the second part of the project, we investigated these genes in vivo. 
After transducing these genes into three different cell types (haematopoietic stem cells, 
polyclonal T cells and monoclonal T cells) individaully, these cells were transplanted into 
Rag-1 deficient mice. A total of 18 HSC/HPC, 17 mature polyclonal T cell and 24 mature 
monoclonal T cell (OT-I) transplanted mice were evaluated (see table 24). From the NPM-
ALK group, all five mice transplanted with transduced mature monoclonal T cells (OT-1) 
developed  leukaemia/lymphoma, while 1 out  of 3 mice transplanted with transduced 
HSCs/HPCs  and 2 out  of 6 mice transplanted with transduced mature polyclonal T cells 
developed  leukaemia/lymphoma. From p21SNFT group, only two mice transplanted with 
transduced mature monoclonal T cells (OT-1) developed leukaemia/lymphoma.   
5.1   Effects of NPM-ALK, Tax and p21SNFT on human T cell lines 
Gammaretroviral vectors encoding control vector, p21SNFT,  Tax or NPM-ALK were 
transduced into two different human T cell lines (PM-1 and Jurkat).  Only single copy 
transduced cells (~15% eGFP positive) were used to achieve the same copy number of each 
used transgene and to decrease the risk of insertional mutagenesis. The risk of insertional 
mutagenesis has already been described [57]. After transduction, the cells were followed up 
for gene marking and cell growth. For NPM-ALK and Tax transduced T cell lines, the eGFP 
markings declined from ~15 to <1% 8 to 10 days after transduction, while the control cells 
transduced with the control gene (eGFP) showed stable expression (see figure 17 A/B). 
Oncogene transduced cells also showed less exponential growth as compared to control 
cells (see figure 17 E/F). For p21SNFT, the eGFP marking declined very slowly from ~15 to 
~6% in both transduced T cell lines (PM-1 and Jurkat) over a period of several weeks, while 
the control cells  transduced with the control gene (eGFP) showed stable expression (see 
figure 17 A/B). The cell growth for p21SNFT transduced cells was comparable  with  the 
control cells in both T cell lines (see figure 17 C/D). The decline in eGFP for p21SNFT 
transduced cells might have been due to survival disadvantage from this gene. As it has Discussion  80
already been shown by a group that p21SNFT causes decreased production of IL-2 
(interleukin 2) in Jurkat T cells [27]. IL-2 is a very important growth factor for T cells. Lack of 
IL-2 might have resulted in the survival disadvantage of p21SNFT expressing T cells.  
As the eGFP marking for NPM-ALK and Tax transduced T cell lines (PM-1 and Jurkat) 
declined from ~15 to <1%, LM-PCR was performed before and after decline of eGFP marking 
in Jurkat cells to further investigate if the cells were still containing the proviral sequence 
coding for NPM-ALK and Tax. For both oncogenes (NPM-ALK and Tax), LM-PCR revealed 
oligoclonal pattern in the cells expressing ~15% eGFP, while the cells expressing <1% eGFP 
showed only one band, which has been the internal control (see figure 18). There are two 
possibilities for this fact. On the one hand, it might be that  an error during the LM-PCR 
performance occured, resulting in the amplification of only the internal control band, which is 
extremely unlikely. On the other hand, it is more likely that the signal for the internal control 
band was caused by a contamination with a plasmid during DNA extraction from the cells. A 
contamination during the LM-PCR procedure can be excluded because the negative control 
revealed no signal (data not shown). The band appearing at ~50bp length was subcloned, 
but it did not reveal any usable sequence.  
Another way to test if there has still been proviral sequence in the transduced cell lines, 
would have been the usage of a second restriction enzyme in the beginning of the LM-PCR 
procedure (step 1) in a separate approach. In this approach, the restriction enzyme Tsp509I 
would have been used. In future experiments, one could perform LM-PCR with the MspI, 
which digests the palindromic nucleotide sequence CCGG instead of AATT in the case of the 
usage of Tsp509I. Via this approach, using 2 or 3 different restriction enzymes, probability of 
finding all gammaretroviral insertions in the cells genome  is  increased. 
Thus, no any growth or proliferation promoting effect of all these oncogenes on both human T 
cell lines was observed, rather those cells probably died, indicated by decreased exponential 
growth, decline in eGFP marking and the absence of the proviral sequence in the LM-PCR 
(in NPM-ALK and Tax transduced cells). In contrast to that, control vector transduced cells 
grew better with stable expression of eGFP marking. Unfortunately, only one LM-PCR was 
performed with DNA, extracted from control vector transduced cells 5 days after transduction, 
but not from later time points. These time points might have shown some interesting 
integration sites that might  cause the survival advantage of these cells due to possible 
transactivation of surrounding genes (proto-oncogenes). In this case, one could have 
investigated the altered gene expression of these surrounding genes via qPCR or microarray 
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5.2   Transformation potential of NPM-ALK in primary murine cells 
5.2.1 Transformtion of murine HSCs/HPCs after gammaretroviral 
mediated NPM-ALK transduction 
Haematopoietic stem cells/haematopoietic progenitor cells (HSCs/HPCs) were transduced 
with the potent T cell oncogene  NPM-ALK
 
and transplanted into Rag-1 deficient mice. 1 out 
of 3 mice transplanted with transduced HSCs/HPCs developed leukaemia/lymphoma 158 
days after transplantation. In FACS analysis, no phenotype of the tumor could be identified. 
Although the tumor showed different cell populations which were positive for the donor cell 
marker (CD45.1) and either  T cell,  B cell, NK cell or myeloid cell marker, but it did not 
express any eGFP marking (see section 4.5.3.1.3). The LM-PCR revealed an oligoclonal 
pattern of the tumor (figure 28).  The histopathologic analysis revealed this tumor as 
anaplastic lymphoma
 
phenotype (see figure 23).  As the tumor cells lost eGFP marking, 
RTqPCR or microarray analysis should be performed to look for the expression of the NPM-
ALK and surrounding genes. The tumorigenic role of NPM-ALK transduced bone marrow 
precursors in a mouse model has already been described by others. Here, 4 out of 7 mice 
developed tumors, which were  large B cell lymphomas  [61]. By using T cell lineage-
restricted promoters, transgenic mice have been established in which NPM-ALK expression 
leads to T cell transformation [62,63]. Similarly, in these NPM-ALK transgenic models, B cell 
lymphomas were also observed [62,64,65], suggesting that the inappropriate activation of 
ALK in B cells can elicit signals promoting their transformation and supporting the 
pathogenetic role of this kinase in the rare ALK-DLBCL. Therefore, in further steps, this tumor 
should be analyzed for BCR/TCR rearrangement on genomic level and further markers of 
early B and T cell development to identify if it is B cell or T cell lymphoma.    
5.2.2 Transformation of murine polyclonal T cells after 
gammaretroviral mediated NPM-ALK transduction 
Only 2 out of 5 mice transplanted with NPM-ALK transduced polyclonal T cells developed 
leukaemia/lymphoma 153-250 days after transplantation. In FACS analysis, no phenotype of 
the tumors could be identified, as the tumors showed different cell populations which were 
positive for donor cell marker  (CD45.1) and either  T cell,  B cell, NK cell or myeloid cell 
marker but did not express any eGFP marking except one tumor which expressed 2% eGFP 
as well (see section 4.5.3.1.2). These 2% eGFP positive cells did not show any lineage 
specific marker. The LM-PCR revealed monoclonal to oligoclonal pattern of these tumors 
(see figure 28). The histopathologic analysis revealed these tumors as  anaplastic lymphoma
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(see figure 23). As the tumor  cells lost eGFP marking,  RTqPCR or microarray analysis 
should be performed to look for the expression of NPM-ALK and surrounding genes. In 
further steps, these tumors should be analyzed for BCR/TCR rearrangement on genomic 
level and for additional markers of early lymphoid development to know if they are B cell or T 
cell lymphomas. Although before transplantation we transduced T cells, but it might have 
been possible that some B cells survived in the culture and were transduced with NPM-LK 
before transplantation. In our group the experiments are ongoing in which some of B cells 
survived in the cell culture and were transduced with the oncogene ( TrkA). It has already 
been shown that mature B cells can be transformed [9]. Although the relative resistance to 
transformation of polyclonal T cells by potent T cell oncogenes LMO2,  TrkA and TCL-1 has 
already been investigated in our group [55], but in comparison to the oncogenes used 
previously,  NPM-ALK is known to cause mature form of T cell and also B cell 
leukaemia/lymphoma [61,62,63]. Additionally, it might be possible that NPM-ALK is a more 
potent oncogene and therefore could transform mature polyclonal T cells. Furthermore, as 
only 2 out of 6 mice transplanted with NPM-ALK transduced polyclonal T cells developed 
leukaemia/lymphoma  after  longer latencies (153-250 days after transplantation) in 
comparison to all 5 mice transplanted with NPM-ALK transduced monoclonal mature T cells 
(OT-I), which developed leukaemia/lymphoma within shorter latencies (45-64 days after 
transplantation), an interesting potential control mechanism in the  leukaemogenesis by 
mature T cells could be the clonal competition of polyclonal mature T cells for stimulatory 
niches, which is well described in the following section 5.2.3.  
5.2.3 Transformtion of murine monoclonal T cells after 
gammaretroviral mediated NPM-ALK transduction 
In our experimental setup, we used monoclonal mature  T cells (OT-I) to analyze the 
hypothesis of  clonal competition by  polyclonal  T  cells  for  stimulatory  niches.  The  peripheral 
T lymphocytes get their survival signal by interacting with specific major histocompatibility 
complex (MHC)/self peptide complex, presented by APC (antigen presenting cells).   
Homeostatic mechanisms conserve the polyclonality of the T cell population [66] and 
regulates the proliferation of peripheral T lymphocytes [67]. This mechanism could possibly 
hinder the outgrowth of premalignant T cell clones. In a polyclonal situation, potentially 
preleukaemic clones would not get sufficient survival signals because of the competition 
within the stimulatory niches and thus their out growth would be controlled (see figure 30 A). 
Therefore, OT-I TCR transgenic mice were chosen as donors to use monoclonal mature T 
cells to exclude polyclonal situation. These monoclonal T cells are mainly CD8+ in these Discussion  83
mice models. These mice express only one transgenic TCR [68] and thus the control 
mechanism of the MHC-TCR niches is abolished.               
Figure 30. Suggested niche model in controlling preleukaemic clones. (A) Polyclonal situation. 
All stimulatory niches are occupied by competing T cells. In this situation the preleukaemic clones 
could either be lost or controlled through the homeostatic mechanisms. (B) Monoclonal situation 
(OT-I transplant). All niches are free to be occupied by preleukaemic clones, as there is no 
competition due to absence of polyclonal T cells. Potential leukaemic clones would find sufficient 
stimulatory niches to attain full growth and possibly develop leukaemia/lymphoma. Modified after [66].   
The hypothesis is that, by the restriction of the T cell repertoires, free MHC niches could 
possibly be occupied by potentially transformable T cells. The preleukaemic clone could 
attain a full growth signal within the open niches without any competition of polyclonal T cells 
(see figure 30 B). 
For this purpose, after transducing the monoclonal T cells (OT-I) with NPM-ALK, Rag-1 
deficient mice were transplanted with these transduced cells. All  5  mice  from this group 
developed leukaemia/lymphoma after short latencies (45-64 days post transplantation). In 
FACS analysis, these tumors were positive for 6 to 45% eGFP marking, but very weak 
percentages of different cell populations like, TCR /
 
(common TCR), V 2/V 5 (OT-I specific 
TCR), CD8, CD4, CD19, NK1 (natural killer), and a high percentage of CD11b (myeloid 
marker) population. The eGFP expressing cells did not express any lineage marker (see 
section 4.5.3.1.1). The histopathologic analysis revealed  anaplastic lymphoma phenotype 
(see figure 23). LM-PCR revealed an oligoclonal to monoclonal pattern of these tumors (see 
figure 27).  
As all 5 mice from this group (NPM-ALK transduced OT-I) developed leukaemia/lymphoma in 
comparison to NPM-ALK transduced HSCs transplanted mice, from which 1 out of 3 mice 
and polyclonal T cell transplanted mice from which 2 out of 6 mice developed 
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leukaemia/lymphoma, these results might support our hypothesis of  stimulatory niches
 
(mentioned above). Higher portions of polyclonal T cells might have occupied an increased 
number of stimulatory niches and controlled the full growth of premalignant clones. However 
in contrast to that, it was described that activated/memory T cells do not dependent upon 
MHC-TCR interaction for survival signals and their proliferation is essentially controlled by 
cytokines [69,70,71]. In the presented work, only memory T cells were used since the ex vivo 
stimulation with anti CD3/CD28 antibodies converted the naive mature T cells to memory T 
cells [72]. On the other hand, it could be shown that after the ablation of TCR, naive and 
memory T cells disappeared due to deprivation of MHC-TCR signal [73,74]. It would also be 
possible that OT-I lymphocytes have an increased, so far undiscovered, intrinsic 
transformation potential. Moreover, OT-I TCR could be particularly activated by high MHC 
affinity and thus support a malignant transformation. The high affinity of OT-I TCR was 
described  previously  [75,76]. In order to examine  this hypothesis more closely for clonal 
compitition, experiments are ongoing in our group in which oncogene transduced monoclonal 
OT-I T cell population is cotransplanted with different populations of polyclonal T cells.                                    
5.3   Transformation potential of p21SNFT 
5.3.1 Transformtion of murine monoclonal T cells after 
gammaretroviral mediated p21SNFT transduction 
From p21SNFT group, 2 out of 7 mice transplanted with transduced monoclonal mature T 
cells (OT-I) developed leukaemia/lymphoma 144-200 days after transplantation, while none 
of the mice transplanted with p21SNFT transduced polyclonal T cells or haematopoietic stem 
cells developed leukaemia/lymphoma, although they highly expressed eGFP (see section 
4.5.3.2). An interesting potential mechanism in the leukaemogenesis by monoclonal mature T 
cells (OT-I) could be the free stimulatory niches (MHC/self peptide),  occupied by the 
transformed clones, which has already been described in the section 5.2.3. Histopathologic 
analysis of these tumors revealed  anaplastic lymphoma
 
(see figure 25).  LM-PCR was 
performed for one of these tumors which revealed monoclonal pattern (see figure 29). In 
FACS analysis, these tumors showed high eGFP and interestingly CD19 expression (see 
4.5.3.2.1). Although CD19 is a specific marker for B cells, it can aberrantly be expressed by T 
cell leukaemia/lymphoma [77,78]. Therefore, this tumor should be investigated for BCR/TCR 
rearrangement  on genomic level to indentify if they are B cell or T cell lymphomas. As 
already mentioned that, before transplantation we transduced T cells with these oncogenes, 
but it might have been possible that some B cells survived in the culture and were transduced 
with p21SNFT before transplantation. In our group the experiments are ongoing in which the Discussion  85
B cells survived in the T cell culture and were transduced with the oncogene ( TrkA). It has 
already been shown that mature B cells can be transformed [9].  
5.3.2 Mice transplanted with p21SNFT  transduced HSCs/HPCs and 
polyclonal T cells 
None of the mice transplanted with p21SNFT transduced HSCs/HPCs and polyclonal T cells 
developed  leukaemia/lymphoma  over the followup of ~240 days after transplantation, 
although they highly expressed eGFP for the transgene (see 4.5.3.2). In our experimental 
setup, from the whole p21SNFT group, only  2 out of 7 mice transplanted with p21SNFT 
transduced monoclonal T cells (OT-I) developed leukaemia/lymphoma 144-200 days after 
transplantation. The observation period and the number of transplanted mice are too small 
and need to be increased for further studies. Therefore, it might be possible that after a 
longer observation period, these mice develop leukaemia/lymphoma.  
5.4   Tax transplanted group 
None of the Tax transplanted mice develop leukaemia/lymphoma. Furthermore, the 
recipients did not show any eGFP marking in the periphery and lymphatic organs after a 
followup of ~250 days post-transplantation, although they expressed donor cell (CD45.1 or 
OT-I) and T cell (CD3) markers. To further investigate if Tax-transduced cells were present in 
the recipients, LM-PCR was performed by isolating DNA from one mouse of each Tax-
transplanted group (HSC, polyclonal T cell and OT-I T cell group). For this purpose, animals 
were sacrificed and DNA was isolated from the splenocytes. LM-PCR revealed oligoclonal 
pattern of the transduced cells in all three group animals (see section 4.5.4), which indicates 
that  Tax transduced cells were still repopulating the recipients, but did not express the 
transgene anymore. It might be possible that the gene modified cells silenced or mutated the 
transgene. It has already been shown that the HTLV-I Tax protein is required for the virus to 
transform cells [22]; however, Tax transcripts are detected in only ~40% of all ATLs. 
Analyses of HTLV-I proviruses and Tax transcripts in ATL cells revealed three ways in which 
cells can silence Tax expression, which are: 
 
Accumulation of nonsense mutations, insertions and deletions in Tax  [23,24].  
 
Silencing viral transcription by DNA methylation of the Provirus [24,25]. 
 
Deletion of the proviral 5 LTR  [26].  
The currently accepted view for silencing of Tax is that, it is required to initiate transformation, 
but is not required later to maintain the transformed phenotype of ATL cells. As Tax is the 
main target of the host s CTLs (cytotoxic T lymphocytes), cells that down-regulate  Tax Discussion  86
expression (using one of the three genetic or epigenetic means described above) have an 
advantage in evading immunosurveillance and are preferentially selected in vivo during 
disease progression [24]. In our used mouse models, Tax transduced cells might have down-
regulated the Tax gene by the mechanisms mentioned before. Furthermore, another group 
has shown that only few Tax-transgenic mice develop leukaemia/lymphoma 18 months after 
birth [79]. In our Tax-transplanted mice, the observation period is still too short (<260 days). It 
might be possible that these mice develop leukaemia/lymphoma after a longer observation 
period.  
5.5   Integration site analysis of gammaretroviral vectors in the 
tumors 
Gammaretroviral integration sites were analyzed via LM-PCR  for all induced tumors. For 
NPM-ALK and p21SNFT oncogene vectors, genomic regions flanking the retroviral 
integrations in tumor cells were obtained by using LM-PCR. They were sequenced and 
aligned to the mouse genome to identify adjacent genes that might have a cooperative effect 
with the oncogenes. Hit loci were examined for the nearest genes to the vector integrations 
as well as the genes within a 200kb upstream and downstream window. Genes in this 
window were analyzed for appearance in the RTCGD [56] and NCBI database, which 
describe the preferential integration of gammaretroviruses and a list of mouse genome, 
respectively. When comparing genes within +/-200kb window of the integrations with RTCGD 
database,  from  NPM-ALK_polyclonal  T cell A3, only 1 out  of 29 integration site flanking 
genes (~3%) was found in the RTCGD, which was Irak2, while from p21SNFT_OT-I A3, 2 out 
of 9 integration site flanking genes (22%) were found in the RTCGD, which were Hck and 
Plagl2.  In the other tumors of NPM-ALK group, the integration site flanking genes were not 
found in the RTCGD database. But in general, when aligned to the mouse genome, there 
were some interesting genes near the transgene integrations (see section 4.5.5.3) which are 
known to play an important role in cell cycling, survival, proliferation and apoptosis. Some of 
those are described as follows:  
In NPM-ALK_OT-I group tumors, Jak3 and Pak4 genes were present near the integration of 
the transgene. Jak3 is known to causes increased cell survival and proliferation. It is involved 
in  one of the important pathways (Jak3/Stat3)  by which NPM-ALK exerts its oncogenic 
effects to induce leukaemia/lymphoma [19]. For Pak4, one group has shown that its 
overexpression or activation plays a key role in oncogenic transformation due to its ability to Discussion  87
promote cell survival and subsequent uncontrolled proliferation. It is overexpressed in many 
types of cancers, like, colon, esophageal and mammary tumors [80].  
In NPM-ALK_HSC/HPC group tumor, TRAFS was present near the transgene integration, 
which prevents the lymphoma cells from spontaneous and induced apoptosis [81].  
In  p21SNFT_OT-I group tumor, PLAG1 was present near the transgene integration. 
Oncogenic activation of PLAG1 is a crucial event in human tumours like, pleomorphic 
adenomas of the salivary glands, lipoblastoma, hepatoblastoma, and acute myeloid 
leukaemia (AML) [82].  
These  genes might have contributed to the development of leukaemia/lymphoma  in both 
groups (NPM-ALK and p21SNFT induced tumors) described above. The risk of insertional 
mutagenesis due to retroviral mediated gene transfer was previously described [58],[59],[60]. 
A detailed list of all integration-sites in our induced tumor groups can be found in the 
supplementary data (see appendix 7.3). Infact, these results do not prove that the transgene 
(NPM-ALK/p21SNFT) was up-regulated by the surrounding genes via LTR transactivation, or 
its insertion caused transactivation of surrounding genes. This should be checked by further 
experiments like microarray, or RT or qPCR to look for the expression of these genes.  
5.6   Conclusion 
All mice transplanted with NPM-ALK transduced mature monoclonal T cells (OT-I) developed 
leukaemia/lymphoma  as compared to  NPM-ALK  transduced  HSCs/HPCs and mature 
polyclonal  T cells transplanted mice, from which only few recipients developed 
leukaemia/lymphoma. Furthermore, from the p21SNFT group, 2 out of 7 mice transplanted 
with mature monoclonal T cells (OT-I) developed leukaemia/lymphoma. Thus, in comparison 
to polyclonal T cells, monoclonal T cells (OT-I) are more readily transformable with T cell 
oncogenes NPM-ALK and p21SNFT. Competition of T cell clones might control the outgrowth 
of  pre-malignant  T cells  and  which may be the mechanism for the relative resistance of 
polyclonal mature T cells to transformation. The mechanisms underlying the control of 
malignant outgrowth in polyclonal T cell populations will be further analyzed in our group on 
the molecular level and on the level of clonal dynamics.     References  88
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7.  Appendix
 
7.1   Abbreviations 
ALL  Acute lymphoblastic leukaemia 
AML  Acute myeloid leukaemia 
AAV  Adeno-associated virus 
bp  Basepair 
BSA  Bovine serum albumin 
cDNA  Complimentary DNA 
CIS  Common integration sites 
ddH2O  Deionized distilled water 
DMEM Dulbecco s Modified Eagles Medium 
DMSO  Dimethyl sulfoxide 
DN  Double negative 
DNA  Deoxyribonucleic acid 
dNTP  Deoxyribonucleotides 
DP  Double positive 
E.coli  Escherichia coli 
EDTA  Ethylendiamintetraessigsäure 
eGFP  Enhanced green fluorescent protein 
Env  Envelope 
EtOH  Ethanol  
FACS  Fluorescence activated cell sorting 
FCS  Fetal Calf Serum 
Gag  Group-specific antigen 
GALV  Gibbon Ape leukaemia virus 
HBSS  Hanks buffered salt solution 
HE  Haematoxilin eosin 
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HIV  Human immunodeficiency virus 
HRPO  Horse-radish peroxidase  
HSC/HPC  Haematopoietic stem cell/ Haematopoietic progenitor cell  
HTLV-I Human  T-lymphotropic Vírus type 1 
Ig  Immunoglobulin  
IL  Interleukin 
IN  Integrase 
IRES  Internal ribosome entry site 
IVC  Individual ventilated cage 
kb  Kilobase 
kDa  Kilodalton Appendix  93
LB  Lennox L Broth base 
LIC  Leikemia initiating cell 
LM-PCR  Ligation mediated Polymerase chain reaction 
LN  Lymph node 
LTR  Long terminal repeats 
M  Molar 
MA   Matrix protein 
mcs  Multiple cloning site 
MHC  major histocompatibility complex 
min.  Minute 
MLV  Murine leukaemia virus 
MNC  Mononuclear cells 
MPBST  5% milk in PBST 
mRNA  Messenger RNA 
MSA  Murines Serum Albumin 
NC  Nucleocapsid protein 
NEB   New England Biolabs 
NHL  Non Hodgkin Lymphoma 
OD  Optical density 
ORF  Open reading frame 
PAGE  Polyacrylamide gel electrophoresis 
PBL  Peripheral blood lymphocytes 
PBS  Phosphate buffered saline 
PBST  Phosphate-buffered saline   Tween 20 
PE  Phycoerythrine 
PCR  Polymerase chain reaction 
Pol  Polymerase 
PR  Protease 
RCV   Replication competent virus 
RCR  Replication competent Retrovirus 
RNA  Ribonucleic acid 
rpm  Rounds per minute 
RPMI  Roswell Park Memorial Institute  
RRE  Rev responsive element 
RT  Reverse transcriptase 
RT  Room temperature 
SCID  Severe Combined Immunodeficiency 
SDS  Sodium dodecyl sulfate 
Sec.  Second 
SIN  Self inactivating 
SV40  Simian virus 40 
TAE  Tris-Acetat-EDTA 
TCR  T cell receptor 
TM  Transmembrane Appendix  94
TRIS  Tris(hydroxymethyl)amino-methane 
TFG  TRK-fused gene 
UTR  Untranslated region 
UV  Ultra-violet light 
V  Volt 
v/v  volume per volume 
w/v  weight per volume 
wPRE  Woodchuck hepatitis virus post-transcriptional regulatory element 
WT  Wild type 
μg  Micrograms 
μl  Microliter 
μm  Micrometer 
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7.2    Plasmid maps  
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